REVIEW article

Front. Mol. Neurosci., 23 June 2022

Sec. Methods and Model Organisms

Volume 15 - 2022 | https://doi.org/10.3389/fnmol.2022.828055

Epigenetic Effects of Addictive Drugs in the Nucleus Accumbens

  • Department of Neuroscience, Medical University of South Carolina, Charleston, SC, United States

Article metrics

View details

21

Citations

6,4k

Views

1,6k

Downloads

Abstract

Substance use induces long-lasting behavioral changes and drug craving. Increasing evidence suggests that epigenetic gene regulation contributes to the development and expression of these long-lasting behavioral alterations. Here we systematically review extensive evidence from rodent models of drug-induced changes in epigenetic regulation and epigenetic regulator proteins. We focus on histone acetylation and histone methylation in a brain region important for drug-related behaviors: the nucleus accumbens. We also discuss how experimentally altering these epigenetic regulators via systemically administered compounds or nucleus accumbens-specific manipulations demonstrate the importance of these proteins in the behavioral effects of drugs and suggest potential therapeutic value to treat people with substance use disorder. Finally, we discuss limitations and future directions for the field of epigenetic studies in the behavioral effects of addictive drugs and suggest how to use these insights to develop efficacious treatments.

Introduction

Substance use disorder (SUD) is defined by the DSM-5 as problematic patterns of “using alcohol or another substance that results in impairment in daily life or noticeable distress” (American Psychiatric Association, 2013). SUD contributes to major health problems in society, like the current opioid crisis in the United States (Seth et al., 2018; Volkow and Blanco, 2021). People suffering from SUD can severely impact their own personal health and negatively impact society around them, but we still only have a limited understanding of how a SUD is formed and maintained in the brain. Of particular note, our knowledge of how substance use-promoting mechanisms in the brain are maintained for years or even decades after the last use of a substance is incomplete. One possible mechanism for these long-lasting changes in the brain that promote SUD involves epigenetic changes. Epigenetic mechanisms provide a molecular basis for long-term gene regulation following interactions with the environment like using addictive substances repeatedly over time. Understanding these mechanisms is a major goal of epigenetic research on SUD. Below we will discuss how epigenetic regulation occurs, some of the evidence for epigenetic regulation in SUD in humans and in rodent models, and some challenges facing the field going forward.

Introduction to Drug-Related Behaviors

Most of the references below discuss findings from rodent models of SUD. Broadly speaking, rodent models can be separated into two classes.

Experimenter administered (non-contingent) models. These include conditioned place preference (CPP), locomotor sensitization, and alcohol vapor exposure where the rodents have no choice in drug exposure.

Self-administration (contingent) models. These models allow the rodents more choice over when to take drugs. These assays include alcohol drinking (2-bottle choice, drinking-in-the-dark) and drug self-administration (heroin, cocaine, methamphetamine, nicotine, etc.).

As we will detail below, these contingent and non-contingent experimental models sometimes indicate a similar role of epigenetic regulators in the development or maintenance of drug reward and/or conditioned behaviors. However, in other cases, similar manipulations produce different effects depending on the behavior. In this text, we refer to one or more of these behaviors (regardless of contingent or non-contingent) as “drug-related” behaviors.

Genetic Versus Epigenetic Mechanisms of Substance Use Disorder

Drug-related behaviors can be influenced by both genetic and epigenetic mechanisms.

Genetic Mechanisms of Substance Use Disorder

Genetic mechanisms involve inheritable DNA base pair differences, and a consensus of the field is that about 50% of the vulnerability to develop a SUD is genetic (Wang et al., 2012; Reilly et al., 2017). For instance, clear genetic effects exist for certain alleles of alcohol dehydrogenase (ALD) to reduce excessive alcohol use (Wang et al., 2012), and adoption studies have shown that genetic inheritance plays a stronger role than an individual’s familial environment in predicting who will develop alcohol use disorders (Schuckit et al., 1972; Goodwin et al., 1973, 1974, 1977; Reilly et al., 2017).

Epigenetic Mechanisms of Substance Use Disorder

In contrast to genetics, epigenetics in its simplest definition means “above” or “on top of” (“epi” – Greek) genetics and broadly refers to the ability to induce long-lasting changes based on environmental influences instead of DNA base pair differences. The term “epigenetics” has many definitions though (Deans and Maggert, 2015; Allis and Jenuwein, 2016), and here we will discuss the two most common in the literature. The first definition refers strictly to transgenerational, inherited changes depending on the environment of the offspring’s parents. The second definition involves the regulation of gene expression through changes in DNA methylation, histone post-translational modifications (PTMs), and chromatin structure. We discuss evidence for each of these below.

Transgenerational Epigenetic Mechanisms

Epigenetic mechanisms can influence drug-related behaviors of offspring. For instance, if rats self-administer cocaine before they reproduce, their male offspring will - surprisingly - have reductions in cocaine self-administration behavior (Vassoler et al., 2013) and cocaine locomotor sensitization in the 1st generation (F1), but not the 2nd (F2) generation (Wimmer et al., 2019). A similar finding was reported for morphine exposed fathers and their F1 and F2 offspring (Vassoler et al., 2017). In addition, nicotine exposed males sire F1 generation offspring with increased spontaneous locomotor activity and learning deficits. Furthermore, males in the F2 generation also display deficits in learning (McCarthy et al., 2018). In addition, similar findings have been shown in alcohol models, where males that had chronic alcohol exposure sire F1 offspring that later display reductions in alcohol self-administration (Nieto et al., 2022). Somewhat in contrast to these studies, however, other studies have suggested that the offspring of rats exposed to cocaine have increases in the motivation for cocaine in the F1 and F2 generations (Le et al., 2017). Together, this indicates that while most reports do show transgenerational effects, their results are not always similar. Despite the evidence for transgenerational epigenetic effects, most studies of epigenetic mechanisms in rodent models focus on a different aspect of substance-induced epigenetic regulation.

Environmental Epigenetic Mechanisms

A second definition of epigenetics is the regulation of gene expression caused by environmental changes. This definition is similar to our previous review (Anderson et al., 2018b) and other reviews in the field (Jaenisch and Bird, 2003; Nestler, 2013; Kenny, 2014; Allis and Jenuwein, 2016; Werner et al., 2021). These gene expression changes can occur through alterations in DNA methylation, histone post-translational modifications (PTMs), and chromatin structure as detailed below.

DNA Methylation. DNA can be methylated on cytosine residues when they are immediately followed by a guanine residue (CpG sites). These methylation marks can inhibit or promote transcription depending on their location on DNA (Christman et al., 1977; Bird and Southern, 1978; Desrosiers et al., 1979; Jones and Taylor, 1980) by reducing the binding of transcription initiators or by recruiting repressor proteins like methyl-CpG binding protein 2 (MeCp2) (Meehan et al., 1989, 1992; Lewis et al., 1992; Deng et al., 2010, 2014).

Histone Post-translational Modifications. DNA in the nucleus is wrapped around sets of 8 proteins called histones to form a nucleosome, the basic structural unit of the chromosome. There are several types of histones including H2A, H2B, H3, and H4 (Luger et al., 1997) and they can undergo a variety of PTMs on their N-terminal tails that can influence transcription and form the basis of the “histone code” (Allis and Jenuwein, 2016).

Histone Acetylation

The first such regulation discovered was that increased acetylation of histones results in increased transcription (Allfrey et al., 1964). This effect may be caused by increased physical accessibility for transcriptional machinery due to an electrostatic repulsion of the negatively charged phosphates of DNA by negatively charged acetyl groups on histones (Sterner and Berger, 2000; Eberharter and Becker, 2002). In addition, acetylation also recruits regulatory factors like the bromodomain-containing protein Creb-binding protein (CBP) that has histone acetyltransferase activity (HAT) and can increase transcription (Hong et al., 1993; Grunstein, 1997; Yang, 2004; Bannister and Kouzarides, 2011).

Histone Methylation

Histone methylation is another common histone PTM, where a methyl group is attached to a lysine or arginine (Di Lorenzo and Bedford, 2011; Benevento et al., 2015; Zhang et al., 2015). Like acetylation however, methylation also recruits regulatory factors like heterochromatin protein 1 (HP1) to alter transcription (Lachner et al., 2001; Bannister and Kouzarides, 2011; Benevento et al., 2015).

Other Post-translational Modifications

Many more PTMs exist like phosphorylation, sumoylation, ubiquitination, and ADP-ribosylation; however, we will not discuss these in this review.

Chromatin Structure. Histone- and DNA-containing nucleosomes are grouped together into chromatin. Chromatin can consist of dense, compact regions that are transcriptionally repressed and not actively transcribed known as heterochromatin. Heterochromatin can also be subcategorized into constitutive (condensed/not transcribed) and facultative (loose/transcribable under certain conditions). Chromatin can also exist in forms that are easily transcribed known as euchromatin (Huisinga et al., 2006; Delcuve et al., 2009). Drug exposure has been shown to alter chromatin accessibility status through epigenetic mechanisms through DNA methylation and histone PTMs and these mechanisms likely act in concert with one another as we previously described (Anderson et al., 2018b).

Importantly, in this review, we will focus on histone acetylation and histone methylation (Figure 1), but DNA methylation and chromatin structure are also altered by drug exposure in rodent models (Deng et al., 2010, 2014; Massart et al., 2015; Werner et al., 2021).

FIGURE 1

FIGURE 1

Drug exposure induces changes in epigenetic regulation in the nucleus accumbens and alters behavior. (A) Histone modifications are a form of epigenetic regulation that can alter DNA transcription. Two well studied modifications are acetylation (Ac) and methylation (Me). Increases in acetylation typically increase transcription and are thought to be “go” signals (green). In contrast, increases in methylation typically decrease transcription and are considered “stop” signals (red). Drug exposure has been shown to cause changes in histone acetylation (Table 1) and histone methylation (Table 2). (B) Histone acetylation levels of histones can be increased by histone acetyltransferases (HATs) and decreased by histone deacetylases (HDACs). Histone methylation levels can be increased by methyltransferases (MTs) and reduced by demethylases (DMs). Epigenetic proteins that modify histone acetylation and histone methylation are altered by drug exposure (Table 3). (C) Altering the activity of epigenetic proteins via systemic injection of inhibitor or activator compounds can alter drug-related behaviors in rodent models (Table 4). (D) Finally, accumbens-specific manipulations of epigenetic proteins can also alter drug-related behaviors (Table 5). This figure was created in part with biorender.com.

Epigenetic Regulation in the Nucleus Accumbens

The NAc is part of the endogenous reward system and is critically involved in behavioral effects of addictive drugs. Drug exposure activates this system acutely but overtime are hypothesized to “hijack” this circuitry to increase drug-seeking (Nesse and Berridge, 1997). Many studies have examined epigenetic regulation in the NAc and found that many changes in histone acetylation and histone methylation occur after exposure to drugs (Anderson et al., 2018b; Werner et al., 2021). Though many areas in the brain show drug-induced epigenetic regulation like the dorsal striatum (Li et al., 2018), central nucleus of the amygdala, and orbitofrontal cortex (Cates et al., 2018), this review will only focus on the nucleus accumbens (NAc) (Figure 1). Here we summarize the literature in several tables that can be sorted by drug, type of administration (acute, chronic, or self-administered) or by the various drug-induced change in histone acetylation (Table 1) and histone methylation (Table 2) marks reported.

TABLE 1

Histone TargetDrugEffectApproachTissue collection timingType of administrationDrug administrationReferencesPMID
H2K12acCocaine↑ AcetylationIHC with anti H2K12ac1 hrsAcute and ChronicCocaine (10 mg/kg, i.p.)Malvaez et al., 201122114264
H3acCocaine↑ Acetylation at FosB promoterChIP-qPCR1 hrsChronicCocaine (20 mg/kg, i.p.) for 7 daysKumar et al., 200516242410
H3acCocaine↑ Acetylation at BDNF Promoter 2 and Cdk5 promoterChIP-qPCR24 hrsChronicCocaine (20 mg/kg, i.p.) for 7 daysKumar et al., 200516242410
H3acCocaine↑ Acetylation at 1004 promotersChIP on chip24 hrsChronicCocaine (20 mg/kg, i.p.) for 7 daysRenthal et al., 200919447090
H3acCocaine↓ Acetylation at 83 promotersChIP on chip24 hrsChronicCocaine (20 mg/kg, i.p.) for 7 daysRenthal et al., 200919447090
H3acCocaine↑ Acetylation at SIRT1, SIRT2 promotersChIP-qPCR24 hrsChronicCocaine (20 mg/kg, i.p.) for 7 daysRenthal et al., 200919447090
H3acCocaine↑ Acetylation at BDNF Promoter 2ChIP-qPCR7 daysChronicCocaine (20 mg/kg, i.p.) for 7 daysKumar et al., 200516242410
H3acCocaine↑ Acetylation BDNF Promoter 2 and Cdk5 promoterChIP-qPCR24 hrsSACocaine SAKumar et al., 200516242410
H3acCocaine↑ Acetylation at FosB promoterChIP-qPCR24 hrsSACocaine SAKumar et al., 200516242410
H3acCocaine↑ AcetylationWB anti H3Kac3-24 hSACocaine SAWang et al., 201020010550
H3acCocaine↑ AcetylationWB anti H3Kac3-24 hSACocaine SAWang et al., 201020010550
H3acCocaine↑ Acetylation at BDNF-P2, BDNF-P3, FosB, Cdlk5, CaMKIIα, GluR2, NR2A, NR2B, and Psd95.ChIP-qPCRSACocaine SAWang et al., 201020010550
H3K14acCocaine↑ AcetylationIHC with anti H3K14ac1 hAcute and ChronicCocaine (10 mg/kg, i.p.)Malvaez et al., 201122114264
H3K14acCocaine↑ Acetylationnano LC-MS/MSmale progeny of cocaine siresWimmer et al., 201930565761
H3K18acCocaine↓ Acetylationnano LC-MS/MSmale progeny of cocaine siresWimmer et al., 201930565761
H3K27acCocaine↑ Acetylation at Carpt promoterChIP-qPCR24 hChronicCocaine (20 mg/kg, i.p.) for 10 daysCarpenter et al., 202031980629
H3K27acCocaine↑ Acetylation at Nr4a1 and Carpt promoterChIP-qPCR28 daysChronicCocaine (20 mg/kg, i.p.) for 10 daysCarpenter et al., 202031980629
H3K9/K14acCocaine↑ AcetylationWB anti H3K9K14ac0.5 hAcuteCocaine (20 mg/kg) with 3 CPP conditioning sessionsLi Y. et al., 201526377474
H3K9/K14acCocaine↑ Acetylation at CaMKIIα and Cdk5 promoterChIP-qPCR24 hChronicCocaine (20 mg/kg, i.p.) for 7 daysLi Y. et al., 201526377474
H3K9acCocaine↑ AcetylationWB with H3K9ac24 hChronicCocaine (20 mg/kg, i.p.) for 7 daysKennedy et al., 201323475113
H4acCocaine↑ Acetylation at cFos promoterChIP-qPCR0.5 h and 1.5 hAcuteCocaine (20 mg/kg, i.p.)Kumar et al., 200516242410
H4acCocaine↑ Acetylation at FosB promoterChIP-qPCR1 hAcuteCocaine (20 mg/kg, i.p.)Kumar et al., 200516242410
H4acCocaine↑ Acetylation at 692 promotersChIP on chip24 hChronicCocaine (20 mg/kg, i.p.) for 7 daysRenthal et al., 200919447090
H4acCocaine↓ Acetylation at 123 promotersChIP on chip24 hChronicCocaine (20 mg/kg, i.p.) for 7 daysRenthal et al., 200919447090
H4acCocaine↑ AcetylationWB anti H4Kac3-24 hSACocaine SAWang et al., 201020010550
H4acCocaine↑ AcetylationIHC anti H4Kac3-24 hSACocaine SAWang et al., 201020010550
H4acCocaine↑ AcetylationIHC anti H4Kac3-24 hSACocaine SAWang et al., 201020010550
H4acCocaine↑ Acetylation at Egr1 promoterChIP-qPCRSACocaine SAWang et al., 201020010550
H4K12acCocaine↓ AcetylationIHC with anti H4K12ac1 hAcute and ChronicCocaine (10 mg/kg, i.p.)Malvaez et al., 201122114264
H4K16acCocaine↑ Acetylation at numerous promotersChIP-seq24 hChronicCocaine (20 mg/kg, i.p.) for 7 daysFerguson et al., 201525698746
H4K5-16acCocaine↑ Acetylation at FosB promoterChIP-qPCR0.3 hAcuteCocaine (30 mg/kg, i.p.)Levine et al., 201122049069
H4K8acCocaine↑ Acetylation at Fos and Nr4a2 promotersChIP-qPCR0.5 hAcuteCocaine (5 mg/kg) with CPP conditioning sessionsRogge et al., 201323575859
H4K8acCocaine↑ Acetylation at Nr4a1 promoterChIP-qPCR1 hChronicCocaine (20 mg/kg, i.p.) for 7 daysCampbell et al., 202133602824
phospho-H3acCocaine↑ Acetylation at cFos promoterChIP-qPCR0.5 h and 1.5 hAcuteCocaine (20 mg/kg, i.p.)Kumar et al., 200516242410
H3acCocaine + stress↑ Acetylation at BDNF promoter 1ChIP-qPCR0.5 hChronicCocaine binge (15 mg/kg, every hour for 3h) for 2 weeks and Swim stressCleck et al., 200818677617
H3acMethamphe
tamine
↑ AcetylationWB anti H3ac0 hAcuteMETH (1 mg/kg, s.c.) with three CPP conditioning sessionsShibasaki et al., 201121781114
H3acMethamphe
tamine
↑ Acetylation at Nrxn, Syp, Dlg4, Gria1, Grin2a, Grin2b, Camk2a, Creb, Cdk5 promotersChIP-qPCR0 hrsAcuteMETH (1 mg/kg, s.c.) with three CPP conditioning sessionsShibasaki et al., 201121781114
H3K18acMethamphe
tamine
↓ AcetylationWB anti H3K18ac8-24 hAcuteMETH (20 mg/kg, i.p.)Martin et al., 201222470541
H3K9acMethamphe
tamine
↓ AcetylationWB anti H3K9ac1-24 hAcuteMETH (20 mg/kg, i.p.)Martin et al., 201222470541
H4acMethamphe
tamine
↑ Acetylation at Cdk5 promoterChIP-qPCR0 hAcuteMETH (1 mg/kg, s.c.) with three CPP conditioning sessionsShibasaki et al., 201121781114
H4K5acMethamphe
tamine
↑ AcetylationWB anti H3K5ac1-24 hAcuteMETH (20 mg/kg, i.p.)Martin et al., 201222470541
H4K8acMethamphe
tamine
↑ AcetylationWB anti H3K8ac16-24 hAcuteMETH (20 mg/kg, i.p.)Martin et al., 201222470541
H3K14acEthanol↑ AcetylationWB0 hChronicChronic intermittent alcohol vapor exposureFinegersh et al., 201526300722
H3K27acEthanol↑ AcetylationWB anti H3K27ac18 hDrinkingEthanol (daily 10% Ethanol, 2 hrs per day) for 10 days, drinking bottleGriffin et al., 201729109977
H3K27acEthanol↑ Acetylation at FosB promoterChIP-qPCR18 hDrinkingEthanol (daily 10% Ethanol, 2 hrs per day) for 10 days, drinking bottleGriffin et al., 201729109977
H3K9acEthanol↑ AcetylationWB anti H3Kac24 hAcuteEthanol (2.5 g/kg, i.p.) and Ethanol (2.0 g/kg. i.p.) testSprow et al., 201425130590
H3K9acEthanol↑ AcetylationIHC anti H3Kac48-96 hAcuteEthanol (2.5 g/kg, i.p.) and Ethanol (1.5 g/kg. i.p.) testSprow et al., 201425130590
H3K9acEthanol↑ AcetylationWB with anti H4K9ac0 hChronicChronic intermittent alcohol vapor exposureFinegersh et al., 201526300722
H3K9acEthanol↑ AcetylationWB anti H3K9ac24 hChronicEthanol (3 mg/kg, i.p.) for 8th injectionPascual et al., 200919077056
H4acEthanol↑ AcetylationIHC with anti H4ac0.5 hChronicEthanol (2 g/kg, i.p.) for 10 daysBotia et al., 201223110077
H4acEthanol↓ AcetylationWB anti H4ac0 hDrinkingEthanol (20%) access in drinking waterWarnault et al., 201323423140
H4acEthanol↓ AcetylationWB anti H4ac0 hDrinkingEthanol (20%) SAWarnault et al., 201323423140
H4K12acEthanol↑ AcetylationWB anti H4K12ac24 hChronicEthanol (3 mg/kg, i.p.) for 8th injectionPascual et al., 200919077056
H3K18acHeroin↑ AcetylationIHC with anti H3K18ac2 hSAHeroin SA + extinction 14 days + 2hrs after prime-reinstatementChen et al., 201627742468
H4K5acHeroin↑ AcetylationIHC with anti H4K5ac2 hSAHeroin SA + extinction 14 days + 2hrs after prime-reinstatementChen et al., 201627742468
H4K8acHeroin↑ AcetylationIHC with anti H4K8ac2 hSAHeroin SA + extinction 14 days + 2hrs after prime-reinstatementChen et al., 201627742468
H3K14acMorphine↓ AcetylationIHC with H3K14ac1 hChronicChronic morphine (10-60 mg/kg) + naloxone (4 mg/kg)Ciccarelli et al., 201323347952
H3K9acMDMA↓ Acetylation at pN/OFQ promoterpN/OFQ promoter2 hAcuteMDMA (8 mg/kg, i.p.)Caputi et al., 201627989838
H3K9acMDMA↑ Acetylation at proDynorphin promoterproDynorphin promoter2 hAcuteMDMA (8 mg/kg, i.p.)Caputi et al., 201627989838
H3K9acMDMA↓ Acetylation at pN/OFQ promoterpN/OFQ promoter2 hChronicMDMA (8 mg/kg, i.p.) twice per day for 7 daysCaputi et al., 201627989838
H3K14acTHC↑ AcetylationWB24 hChronicTHC (2.5, 5.0 and 10.0 mg/kg, i.p.) twice per day, for 11 daysPrini et al., 201728976920
H3K14acTHC↓ AcetylationWB48 hChronicTHC (2.5, 5.0 and 10.0 mg/kg, i.p.) twice per day, for 11 daysPrini et al., 201728976920
H3acToluene↑ AcetylationIHC with antiH3ac1 hChronicToluene (6000 ppm, 30 min exposure), twice a day for 10 sesession.Sanchez-Serrano et al., 201121146589
H3K9acNicotine↑ AcetylationWB anti H3K9ac0.3 hChronicNicotine (10 mg/ml) in drinking water for 7 daysLevine et al., 201122049069
H3K9acNicotine↑ Acetylation at FosB promoterChIP-qPCR0.3 hChronicNicotine (10 mg/ml) in drinking water for 7 daysLevine et al., 201122049069
H4K5-16acNicotine↑ AcetylationWB anti H4K5toK16ac0.3 hChronicNicotine (10 mg/ml) in drinking water for 7 daysLevine et al., 201122049069
H4K5-16acNicotine↑ Acetylation at FosB promoterChIP-qPCR0.3 hChronicNicotine (10 mg/ml) in drinking water for 7 daysLevine et al., 201122049069

Effects of drug exposure on histone acetylation.

TABLE 2

Histone TargetDrugEffectApproachTissue collection timingType of administrationDrug administrationReferencesPMID
H3K20me2Cocaine↓ MethylationnanoLC-MSMSOffspringSAWimmer et al., 201930565761
H3K27me2Cocaine↓ MethylationnanoLC-MSMSOffspringSAWimmer et al., 201930565761
H3K27me3Cocaine↓ Methylation at pDYN promoterChIP-qPCR0 hrsChronicCocaine (50 mg/kg per day via pumps) for 7 daysCaputi et al., 201424184686
H3K27me3Cocaine↓ Methylation at NOP promoterChIP-qPCR0 hrsChronicCocaine (50 mg/kg per day via pumps) for 7 daysCaputi et al., 201424184686
H3K27me3Cocaine↑ Methylation at Cartpt promoterChIP-qPCR24 hrsChronicCocaine (20 mg/kg, i.p.) for 10 daysCarpenter et al., 202031980629
H3K27me3CocaineNumerous changesChIP-seq24 hrsChronicCocaine (20 mg/kg, i.p.) for 7 daysFeng et al., 201424758366
H3K27me3Cocaine↓ Methylation at Cartpt promoterChIP-qPCR28 daysChronicCocaine (20 mg/kg, i.p.) for 10 daysCarpenter et al., 202031980629
H3K36me3CocaineNumerous changesChIP-seq24 hrsChronicCocaine (20 mg/kg, i.p.) for 7 daysFeng et al., 201424758366
H3K36me3Cocaine↓ MethylationWB24 hrsChronicCocaine (20 mg/kg, i.p.) for 7 daysLi Y. et al., 201526377474
H3K4me1CocaineNumerous changesChIP-seq24 hrsChronicCocaine (20 mg/kg, i.p.) for 7 daysFeng et al., 201424758366
H3K4me2Cocaine↓ MethylationnanoLC-MSMSOffspringSAWimmer et al., 201930565761
H3K4me3Cocaine↑ Methylation at NOP promoterChIP-qPCR0 hrsChronicCocaine (50 mg/kg per day via pumps) for 7 daysCaputi et al., 201424184686
H3K4me3Cocaine↓ Methylation at pN/OFQ promoterChIP-qPCR0 hrsChronicCocaine (50 mg/kg per day via pumps) for 7 daysCaputi et al., 201424184686
H3K4me3Cocaine↑ Methylation at Cartpt promoterChIP-qPCR24 hrsChronicCocaine (20 mg/kg, i.p.) for 10 daysCarpenter et al., 202031980629
H3K4me3Cocaine↑ Methylation at PGC-1a promoterChIP-qPCR24 hChronicCocaine (20 mg/kg, i.p.) for 7 daysChandra et al., 201727939396
H3K4me3CocaineNumerous changesChIP-seq24 hChronicCocaine (20 mg/kg, i.p.) for 7 daysFeng et al., 201424758366
H3K4me3Cocaine↑ Methylation at Nr4a1 and CartptChIP-qPCR28 daysChronicCocaine (20 mg/kg, i.p.) for 10 daysCarpenter et al., 202031980629
H3K9/K27me2Cocaine↑ Mehylation at 898 promotersChIP on chip24 hChronicCocaine (20 mg/kg, i.p.) for 7 daysRenthal et al., 200919447090
H3K9/K27me2Cocaine↓ Methylation at 209 promotersChIP on chip24 hChronicCocaine (20 mg/kg, i.p.) for 7 daysRenthal et al., 200919447090
H3K9me2Cocaine↓ MethylationIHC1 hAcuteCocaine (10 mg/kg, i.p.)Malvaez et al., 201122114264
H3K9me2Cocaine↓ Methylation at FosB promoterChIP-qPCR1 hChronicCocaine (15 mg/kg, i.p) for 10 days, withdrawal 28 days + Challenge Cocaine (15 mg/kg)Damez-Werno et al., 201222836260
H3K9me2Cocaine↓ MethylationIHC1 hChronicCocaine (10 mg/kg, i.p.) for 5 daysMalvaez et al., 201122114264
H3K9me2Cocaine↓ MethylationWB24 hChronicCocaine (20 mg/kg, i.p.) for 7 daysCovington et al., 201121867882
H3K9me2CocaineNumerous changesChIP-seq24 hChronicCocaine (20 mg/kg, i.p.) for 7 daysFeng et al., 201424758366
H3K9me2Cocaine↓ Methylation at the Gabrb3ChIP-qPCR24 hChronicCocaine (20 mg/kg, i.p.) for 7 daysKennedy et al., 201323475113
H3K9me2Cocaine↓ MethylationWB24 hChronicCocaine (20 mg/kg, i.p.) for 7 daysLi Y. et al., 201526377474
H3K9me2Cocaine↓ MethylationWB24 hChronicCocaine (20 mg/kg, i.p.) for 7 daysMaze et al., 201020056891
H3K9me2Cocaine↓ Methylation at Cdk5, p65/NFkB, Arc, FosB, LIMK, BDNF, APRT promotersChIP-qPCR24 hChronicCocaine (20 mg/kg, i.p.) for 7 daysMaze et al., 201020056891
H3K9me2Cocaine↓ Methylation at FosB promoterChIP-qPCR28 DaysChronicCocaine (15 mg/kg, i.p.) for 10 daysDamez-Werno et al., 201222836260
H3K9me2Cocaine↓ Methylation at D2 promoterChIP-PCR30 daysSACocaine SA, acquisiion for 60 days, drug reinstatement at 72 days, and brain collection on 170 dayFlagel et al., 201627114539
H3K9me3Cocaine↑ MethylationWB0.5 hAcuteCocaine (20 mg/kg, i.p.)Maze et al., 201121300862
H3K9me3Cocaine↑ MethylationWB1 hAcuteCocaine (20 mg/kg, i.p.)Maze et al., 201121300862
H3K9me3Cocaine↑ MethylationWB1 hChronicCocaine (20 mg/kg, i.p.) for 7 daysMaze et al., 201121300862
H3K9me3Cocaine↑ Methylation at Auts2 and Caln1 promotersChIP-qPCR24 hChronicCocaine (20 mg/kg, i.p.) for 7 daysEngmann et al., 201728577753
H3K9me3CocaineNumerous changesChIP-seq24 hChronicCocaine (20 mg/kg, i.p.) for 7 daysFeng et al., 201424758366
H3K9me3Cocaine↓ Methylation at numerous sites, 32,956 and 30,412 peaks in saline- and cocaine-treated animals,ChIP-seq24 hChronicCocaine (20 mg/kg, i.p.) for 7 daysMaze et al., 201121300862
H3K9me3Cocaine↓ MethylationWB7 daysChronicCocaine (20 mg/kg, i.p.) for 7 daysMaze et al., 201121300862
H3R2me2aCocaine↑ Methylation at 208 sitesChIP-seq24 hChronicCocaine (20 mg/kg, i.p.) for 7 daysDamez-Werno et al., 201627506785
H3R2me2aCocaine↓ MethylationWB24 hChronicCocaine (20 mg/kg, i.p.) for 7 daysDamez-Werno et al., 201627506785
H3R2me2aCocaine↓ Methylation at 129 siteChIP-seq24 hChronicCocaine (20 mg/kg, i.p.) for 7 daysDamez-Werno et al., 201627506785
H3R2me2aCocaine↓ MethylationWB7 daysSACocaine SA + 7 days withdrawalDamez-Werno et al., 201627506785
H4R3me2aCocaine↑ MethylationWB0.5 hAcuteCocaine (20 mg/kg) with 3 CPP conditioningLi Y. et al., 201526377474
H4R3me2aCocaine↑ MethylationWB24 hChronicCocaine (20 mg/kg, i.p.) for 7 daysLi Y. et al., 201526377474
H4R3me2aCocaine↑ Methylation, CaMKIIα and Cdk5 promoterChIP-qPCR24 hChronicCocaine (20 mg/kg, i.p.) for 7 daysLi Y. et al., 201526377474
H4R3me2aCocaine↑ MethylationWB7 daysChronicCocaine (20 mg/kg, i.p.) for 7 daysLi Y. et al., 201526377474
H3K27me3Methamphe
tamine
↓ MethylationWB1.5 hAcuteMeth with CPP 30 min conditiningAguilar-Valles et al., 201424183790
H3K4me2Methamphe
tamine
↑ MethylationWB1.5 hAcuteMeth with CPP 30 min conditiningAguilar-Valles et al., 201424183790
H3K4me3Methamphe
tamine
↑ Methylation at Oxtr promoterChIP-qPCR1.5 hAcuteMeth with CPP 30 min conditiningAguilar-Valles et al., 201424183790
H3K4me3Methamphe
tamine
↑ Methylation at CCR2 promoterChIP-qPCR24 hChronicMeth (2 mg/kg, s.c.) 5 intermittent treatment with once every 96 hrsIkegami et al., 201020624155
H3K9me2Amphe
tamine
↑ Methylation at c-fos promoterChIP-qPCR5 daysChronicAmphetamine (4 mg/kg, i.p.) for 7 daysRenthal et al., 200818632938
H3K27me3Ethanol↑ Methylation, 3 peaksChIP-seq3 weeksChronicChronic intermittent alcohol vapor exposureJohnstone et al., 202131373129
H3K27me3Ethanol↓ MethylationWB3 weeksChronicChronic intermittent alcohol vapor exposureJohnstone et al., 202131373129
H3K27me3Ethanol↓ Methylation, 90 peaksChIP-seq3 weeksChronicChronic intermittent alcohol vapor exposureJohnstone et al., 202131373129
H3K9me2Ethanol↓ MethylationWB3dChronicChronic intermittent alcohol vapor exposureAnderson et al., 202134013595
H3K4me3Morphine↑ Methylation at Sirt1ChIP-seq24 hChronicMorphine (20 mg/kg, i.p.) for 7 daysFerguson et al., 201324107942
H3K9me2Morphine↑ Methylation 5666 promotersChIP-seq24 hChronicMorphine (20 mg/kg, i.p.) for 7 daysSun et al., 201223197736
H3K9me2Morphine↑ Methylation at Gria1 promoterChIP-qPCR24 hChronicMorphine (20 mg/kg, i.p.) for 7 daysSun et al., 201223197736
H3K9me2Morphine↓ MethylationWB24 hChronicMorphine (20 mg/kg, i.p.) for 5 and 7 daysSun et al., 201223197736
H3K9me2Morphine↓ Methylation 8106 promotersChIP-seq24 hChronicMorphine (20 mg/kg, i.p.) for 7 daysSun et al., 201223197736
H3K9me2Morphine↓ Methylation at Grin2a, Grm5, Grm8 promotersChIP-qPCR24 hChronicMorphine (20 mg/kg, i.p.) for 7 daysSun et al., 201223197736
H3K27me3MDMA↑ Methylation at pDYN promoterChIP-qPCR2 hChronicMDMA (8 mg/kg, i.p.) twice per day for 7 daysCaputi et al., 201627989838
H3K4me3MDMA↑ Methylation at NOP promoterChIP-qPCR2 hAcuteMDMA (8 mg/kg, i.p.)Caputi et al., 201627989838
H3K4me3MDMA↑ Methylation at pDYN promoterChIP-qPCR2 hAcuteMDMA (8 mg/kg, i.p.)Caputi et al., 201627989838
H3K4me3MDMA↑ Methylation at pN/OFQ promoterChIP-qPCR2 hAcuteMDMA (8 mg/kg, i.p.)Caputi et al., 201627989838
H3K9me2MDMA↓ Methylation at pDYN promoterChIP-qPCR2 hAcuteMDMA (8 mg/kg, i.p.)Caputi et al., 201627989838
H3K4me3THC↑ Methylation at Penk geneChIP-qPCR24 hChronicTHC (1.5 mg/kg) for every three days (8 injections) in adolescentTomasiewicz et al., 201222683090
H3K9me2THC↑ MethylationWB24 hChronicTHC (2.5, 5.0 and 10.0 mg/kg, i.p.) twice per day, for 11 daysPrini et al., 201728976920
H3K9me2THC↓ Methylation at Penk geneChIP-qPCR24 hChronicTHC (1.5 mg/kg) for every three days (8 injections) in adolescentTomasiewicz et al., 201222683090
H3K9me2THC↓ Methylation at Penk geneChIP-qPCR30 daysChronicTHC (1.5 mg/kg) for every three days (8 injections) in adolescentTomasiewicz et al., 201222683090
H3K9me2THC↓ MethylationWB48 hChronicTHC (2.5, 5.0 and 10.0 mg/kg, i.p.) twice per day, for 11 daysPrini et al., 201728976920
H3K9me3THC↑ MethylationWB2 hChronicTHC (2.5, 5.0 and 10.0 mg/kg, i.p.) twice per day, for 11 daysPrini et al., 201728976920
H3K9me3THC↑ MethylationWB24 hChronicTHC (2.5, 5.0 and 10.0 mg/kg, i.p.) twice per day, for 11 daysPrini et al., 201728976920
H3K9me3THC↓ Methylation at Penk geneChIP-qPCR30 daysChronicTHC (1.5 mg/kg) for every three days (8 injections) in adolescentTomasiewicz et al., 201222683090
H3K9me3THC↓ MethylationWB48 hChronicTHC (2.5, 5.0 and 10.0 mg/kg, i.p.) twice per day, for 11 daysPrini et al., 201728976920

Effects of drug exposure on histone methylation.

Effects of Drug Exposure on Histone Acetylation

Many addictive drugs cause changes in histone acetylation, including cocaine, methamphetamine, ethanol, opioids, MDMA, THC, toluene, and nicotine.

Cocaine

Cocaine exposure alters many histone acetylation marks in the NAc (Table 1). Cocaine exposure typically increases global acetylation of the histones H3 and H4 in the NAc, likely by increasing individual sites like H2K12, H3K9, H3K14, H3K27, H4K5, H4K8, and H4K16 (Kumar et al., 2005; Cleck et al., 2008; Renthal et al., 2009; Wang et al., 2010; Levine et al., 2011; Malvaez et al., 2011; Kennedy et al., 2013; Rogge et al., 2013; Ferguson et al., 2015; Li Y. et al., 2015; Wimmer et al., 2019; Carpenter et al., 2020; Campbell et al., 2021). Some of these changes in acetylation reflect global changes from whole NAc tissue, but others reflect specific changes at certain promoters (see Table 1 for details). Cocaine-induced decreases in acetylation have also been reported for H3ac, H3K18, H4ac, and H4K12 (Renthal et al., 2009; Malvaez et al., 2011; Wimmer et al., 2019). Cocaine can alter histone acetylation very quickly, but can also produce long-lasting changes as the findings reflect a range of timepoints following the last exposure to cocaine from 20 min to 28 days (Levine et al., 2011; Carpenter et al., 2020). Importantly, while most of these studies used experimenter (non-contingent) exposure, self-administered (contingent) cocaine similarly increases acetylation of histone H3 and H4 at certain promoters 3-24 h after the last self-administration (Kumar et al., 2005; Wang et al., 2010). These data show that exposure to cocaine rapidly changes histone acetylation in many gene promoters, and at least some of these changes can last up to 28 days later.

Methamphetamine

Non-contingent methamphetamine exposure increases pan-H3 acetylation, H4ac at a specific promoter, H4K5, and H4K8 (Shibasaki et al., 2011; Martin et al., 2012). Non-contingent methamphetamine also decreases H3K9 and H3K18 up to 24 hrs later (Martin et al., 2012).

Ethanol

Non-contingent ethanol exposure increases pan-H4 acetylation, and the specific marks H3K14, H3K9, and H4K12 (Pascual et al., 2009; Botia et al., 2012; Sprow et al., 2014; Finegersh et al., 2015). In contrast, self-administered ethanol reduces pan-H4 acetylation (Warnault et al., 2013) and increases H3K27 acetylation (Griffin et al., 2017). These findings suggest that at least some differences (pan-H4 acetylation) are found between contingent and non-contingent rodent models of SUD.

Opioids

Heroin primed reinstatement of drug-seeking behavior following heroin self-administration increases acetylation of H3K18, H4K5, and H4K8 (Chen et al., 2016). Naloxone-precipitated withdrawal administration after chronic non-contingent morphine exposure reduces H3K14 acetylation in the NAc shell (Ciccarelli et al., 2013).

MDMA

Non-contingent MDMA changes H3K9 acetylation at specific promoters (Caputi et al., 2016).

THC

Non-contingent THC increases H3K14ac at 24hrs after the last exposure but then decreases by 48 hrs after the last exposure (Prini et al., 2017).

Toluene

Chronic non-contingent exposure to toluene increases pan-H3 acetylation in the NAc (Sanchez-Serrano et al., 2011).

Nicotine

Chronic nicotine exposure for 7 days through drinking water increases the acetylation level of Histone H3K9 and H4K5-K16 (Levine et al., 2011).

Combined, these studies suggest that most psychoactive, addictive drugs alter histone acetylation in the NAc and highlight that some of these changes may be short-lived and very dynamic (Prini et al., 2017).

Effects of Drugs Exposure on Histone Methylation

The nucleus accumbens also undergoes changes in methylated histone marks following exposure to addictive drugs like cocaine, methamphetamine, ethanol, opioids, MDMA, and THC (Table 2).

Cocaine

Non-contingent cocaine exposure alters many histone methylation sites including H3K27me3, H3K36me3, H3K4me1, H3K4me2, H3K4me3, H3K9/K27me2, H3K9me2, H3K9me3, H3R2me2a, H4K9me3, and H4R3me2a (Adams and Bushell, 1989; Renthal et al., 2009; Maze et al., 2010, 2011; Covington et al., 2011; Malvaez et al., 2011; Damez-Werno et al., 2012, 2016; Kennedy et al., 2013; Caputi et al., 2014; Feng et al., 2014; Li Y. et al., 2015; Chandra et al., 2017; Engmann et al., 2017; Carpenter et al., 2020). These changes include both increases and decreases of methylation at these histone sites (see Table 2 for details on each study). In addition to non-contingent rodent models of SUD, contingent cocaine decreases methylation of H3K9me2 at specific promoters and pan-H3R2me2a as well (Damez-Werno et al., 2016; Wimmer et al., 2019).

Methamphetamine and Amphetamine

Non-contingent methamphetamine exposure decreases H3K27me3 methylation, but increases H3K4me2 and H3K4me3 methylation. Some promoter specific changes remain for at least 24 h (Ikegami et al., 2010; Aguilar-Valles et al., 2014). Amphetamine increases H3K9 methylation on the fos promoter 5 days after the last exposure (Renthal et al., 2008).

Ethanol

Non-contingent alcohol exposure by the chronic intermittent ethanol vapor exposure model alters H3K27me3 and decreases H3K9me2 (Anderson et al., 2021; Johnstone et al., 2021).

Opioids

Non-contingent morphine exposure causes both increases and decreases in H3K9me2 and H3K4me3 that are promoter specific (Sun et al., 2012; Ferguson et al., 2013).

MDMA

Non-contingent MDMA increases H3K27me3 and H3K4me3 at specific promoters and decreases H3K9me2 at others (Caputi et al., 2016).

THC

Non-contingent THC alters H3K9me2 and H3K4me3 levels, some at specific promoters (Tomasiewicz et al., 2012; Prini et al., 2017). Of note, THC causes bidirectional changes in H3K9me2 over 1 vs 2 days after the last exposure (Prini et al., 2017) suggesting some of these histone changes may be very short-lived and highly dynamic. Also, some of these THC-induced changes last up to 30 days later at specific promoters (Tomasiewicz et al., 2012).

General Conclusions on Drug-Altered Histone Post-translational Modifications

Some similar general conclusions can be drawn when examining both histone acetylation and histone methylation following exposure to drugs exposure (Tables 1, 2).

First, different drugs cause different changes in the histone marks. This suggests no clear common “histone code” for drug exposure in the NAc. For instance, cocaine, ethanol, and THC lead to increases in H3K14ac cocaine (Malvaez et al., 2011; Kennedy et al., 2013; Finegersh et al., 2015; Prini et al., 2017), but morphine leads to a decrease (Ciccarelli et al., 2013). Differences in study design and timepoints could affect these findings, for instance, H3K14ac is increased 24 h after THC, but reduced 48 h later (Prini et al., 2017).

Second, most of these histone PTM changes are present at very early timepoints following the last exposure to an addictive drug. In addition, these histone acetylation and histone methylation changes appear to occur very rapidly - even after an acute dose (Martin et al., 2012; Godino et al., 2015) - and are likely highly dynamic or short-lived. In other words, there are large signaling changes in epigenetic marks shortly after the last drug exposure, but most of these changes appear to return to baseline levels following longer timescales.

Third, a small subset of changes at certain gene promoters appear to persist for longer periods of time after the last drug exposure. For instance, increased H3 acetylation at the BDNF promoter (an important mediator of drug-related behaviors (Graham et al., 2007; Bahi et al., 2008; Lobo et al., 2010; Li et al., 2013; Anderson et al., 2017) is observed after 7d withdrawal (Kumar et al., 2005) and increased methylation of H4R3me2a is observed at both 1d and 7d (but not 14d) withdrawal from cocaine (Li Y. et al., 2015). Cocaine also leads to a stable decrease in H3K9me2 at the D2 promoter after a month of withdrawal in rats bred for high responding (Flagel et al., 2016). In addition, THC causes lasting changes at H3K9, as a decrease in methylation is observed at the proenkephalin gene promoter at both 1d and 30d withdrawal (Tomasiewicz et al., 2012). Also, chronic intermittent alcohol vapor exposure decreases H3K27me3 after 3 weeks of withdrawal (Johnstone et al., 2021). Finally, cocaine causes an increase in H3K27ac and H3K4me3 at the cartpt promoter that was found at both 1d and 28d of abstinence. This same study also found that H3K27me3 was increased after 1d of abstinence, but was reduced after 28d of abstinence (Carpenter et al., 2020). So, while all classes of drugs exposure led to short term changes in histone marks, at least some of these changes may remain for longer periods of time and could possibly cause long-lasting behavioral changes.

Effects of Drugs on Epigenetic Regulators in the Nucleus Accumbens

Addictive drugs also cause changes to the proteins that regulate histone marks in the NAc, and this suggests that we can alter these drug-induced histone marks by targeting their epigenetic regulators. As shown in Table 3 there are many known candidates that are regulated by drug exposure in the NAc.

TABLE 3

Epigenetic TargetDrugEffectApproachTissue collection timingType of administrationDrug administrationReferencesPMID
HDACsEthanol↓ nuclear activity22 hrsDrinkingEthanol (daily 10% Ethanol, 2 hrs per day) for 10 daysGriffin et al., 201729109977
HDACsNicotine↓ activity0 hrsDrinkingNicotine (10 mg/ml) in drinking water for 7-10 daysLevine et al., 201122049069
HDAC1Amphe
tamine
↑ enrichment on c-fos promoterChIP-qPCR5 daysChronicAmphetamine (4 mg/kg, i.p.) for 7 daysRenthal et al., 200918632938
HDAC1Cocaine↑ binding to G9a and GLP promotersChIP-qPCR4 hChronicCocaine (20 mg/kg, i.p.) for 7 daysKennedy et al., 201323475113
HDAC1Methamphe
tamine
↓ proteinWB1-16 hAcuteMETH (20 mg/kg, i.p.)Martin et al., 201222470541
HDAC2Cocaine↓ protein association with PARP-1 complexesWB0.5 hChronicCocaine (20 mg/kg, i.p.) for 7 daysScobie et al., 201424449909
HDAC2Cocaine↑ mRNAqPCR2 hSACocaine SAHost et al., 201119939859
HDAC2Cocaine↑ proteinIHC2 hSACocaine SAHost et al., 201119939859
HDAC2Ethanol↑ mRNAqPCR18 hSAChronic intermittent access two bottle choice 20% alcohol drinking 3 days per week for 4 weeksSharma et al., 202134837399
HDAC2Methamphe
tamine
↑ proteinWB1-8 hAcuteMETH (20 mg/kg, i.p.)Torres et al., 201526300473
HDAC2Methamphe
tamine
↑ binding to fosB, fra2, and Egr3 promotersChIP-qPCR2 hAcuteMETH (20 mg/kg, i.p.)Torres et al., 201526300473
HDAC2Methamphe
tamine
↑ proteinWB4-24 hAcuteMETH (20 mg/kg, i.p.)Martin et al., 201222470541
HDAC2Nicotine↑ protein1 dayAcuteNicotine (0.4 mg/kg, i.p.) with CPP 4 conditiningFaillace et al., 201525981209
HDAC3Cocaine↓ binding at promoters (Fos, Nr4a2)ChIP-qPCR1 hAcuteCocaine (5 mg/kg, i.p.) with CPP conditiningRogge et al., 201323575859
HDAC3Cocaine↑ binding to Fos and Nr4a1 promotersChIP-qPCR1 hChronicCocaine (20 mg/kg, i.p.) for 7 daysCampbell et al., 202133602824
HDAC3Cocaine↑ mRNA, in D1-MSNqPCR1 hChronicCocaine (20 mg/kg, i.p.) for 7 daysCampbell et al., 202133602824
HDAC3Methamphe
tamine
↓ mRNAqPCR1 hAcuteMETH (20 mg/kg, i.p.)Torres et al., 201626721795
HDAC3Methamphe
tamine
↓ mRNAqPCR8 hAcuteMETH (20 mg/kg, i.p.)Torres et al., 201626721795
HDAC4Cocaine↑ Nuclear ExportWB4 hChronicCocaine (20 mg/kg, i.p.) for 7 daysPenrod et al., 201828635037
HDAC4Cocaine↑ phosphorylationWB4 hChronicCocaine (20 mg/kg, i.p.) for 7 daysPenrod et al., 201828635037
HDAC4Ethanol↓ proteinWB18 hDrinkingEthanol (daily 10% Ethanol, 2 hrs per day) for 10 daysGriffin et al., 201729109977
HDAC4Ethanol↓ protein in the nuclear at 18 hrsWB18 hDrinkingEthanol (daily 10% Ethanol, 2 hrs per day) for 10 daysGriffin et al., 201729109977
HDAC4Ethanol↑ mRNARNA-seq22 hDrinkingEthanol (daily 20% Ethanol, 2 hrs per day) for 6 weeksPozhidayeva et al., 202032085427
HDAC4Methamphe
tamine
↓ mRNAqPCR1 hAcuteMETH (20 mg/kg, i.p.)Torres et al., 201626721795
HDAC4Methamphe
tamine
↓ mRNAqPCR2 hAcuteMETH (20 mg/kg, i.p.)Torres et al., 201626721795
HDAC4Methamphe
tamine
↓ mRNAqPCR8 hAcuteMETH (20 mg/kg, i.p.)Torres et al., 201626721795
HDAC5Cocaine↑ Nuclear ExportIHC0.5 hChronicCocaine (20 mg/kg, i.p.) for 7 daysRenthal et al., 200717988634
HDAC5Cocaine↑ phosphorylationWB0.5 hChronicCocaine (20 mg/kg, i.p.) for 7 daysRenthal et al., 200717988634
HDAC5Cocaine↓ mRNAqPCR1 hAcuteCocaine (5 mg/kg, i.p.) with CPP conditiningRogge et al., 201323575859
HDAC5Cocaine↓ phosphorylationWB1 hAcuteCocaine (20 mg/kg, i.p.)Taniguchi et al., 201222243750
HDAC5Cocaine↓ phosphorylationWB1 hChronicCocaine (20 mg/kg, i.p.) for 7 daysTaniguchi et al., 201222243750
HDAC5Cocaine↓ nuclear localizationIHC2 hSACocaine SAHost et al., 201119939859
HDAC5Cocaine↑ nuclear ImportWB4 hAcuteCocaine (20 mg/kg, i.p.)Taniguchi et al., 201222243750
HDAC5Cocaine↓ phosphorylationWB4 hAcuteCocaine (20 mg/kg, i.p.)Taniguchi et al., 201222243750
HDAC5Cocaine↑ nuclear ImportWB4 hChronicCocaine (20 mg/kg, i.p.) for 7 daysTaniguchi et al., 201222243750
HDAC5Cocaine↓ phosphorylationWB4 hChronicCocaine (20 mg/kg, i.p.) for 7 daysTaniguchi et al., 201222243750
HDAC5Ethanol↓ mRNARNA-seq22 hDrinkingEthanol (daily 20% Ethanol, 2 hrs per day) for 6 weeksPozhidayeva et al., 202032085427
HDAC5Heroin↓ mRNA, humanMicroarrayHumanHeroin overdoseEgervari et al., 201727863698
HDAC6Methamphe
tamine
↑ mRNAqPCR1 hAcuteMETH (20 mg/kg, i.p.)Torres et al., 201626721795
HDAC6Methamphe
tamine
↑ mRNAqPCR2 hAcuteMETH (20 mg/kg, i.p.)Torres et al., 201626721795
HDAC6Methamphe
tamine
↑ mRNAqPCR8 hAcuteMETH (20 mg/kg, i.p.)Torres et al., 201626721795
HDAC7Methamphe
tamine
↓ mRNAqPCR1 hAcuteMETH (20 mg/kg, i.p.)Torres et al., 201626721795
HDAC7Methamphe
tamine
↓ mRNAqPCR2 hAcuteMETH (20 mg/kg, i.p.)Torres et al., 201626721795
HDAC8Methamphe
tamine
↓ mRNAqPCR8 hAcuteMETH (20 mg/kg, i.p.)Torres et al., 201626721795
HDAC9Ethanol↓ mRNANanoString analysis3 weeksChronicChronic intermittent alcohol vapor exposureJohnstone et al., 202131373129
HDAC11Cocaine↑ proteinIHC2 hSACocaine SAHost et al., 201119939859
HDAC11Ethanol↓ mRNAqPCR0.5 hAcuteEthanol (2 g/kg, i.p), challenge at 17 daysBotia et al., 201223110077
HDAC11Ethanol↓ mRNA, sensitized animalsqPCR0.5 hChronicEthanol (2 g/kg, i.p), for 10 days + Ethanol challenge at 17 daysBotia et al., 201223110077
HDAC11Ethanol↑ mRNA in high drinkers6 hDrinkingEthanol drinking sessions (4 drinking and 4 days of abstinence, repeated four times)Wolstenholme et al., 201121698166
HDAC11Methamphe
tamine
↓ mRNAqPCR1 hAcuteMETH (20 mg/kg, i.p.)Torres et al., 201626721795
HDAC11Methamphe
tamine
↓ mRNAqPCR2 hAcuteMETH (20 mg/kg, i.p.)Torres et al., 201626721795
HDAC11Methamphe
tamine
↓ mRNAqPCR8 hAcuteMETH (20 mg/kg, i.p.)Torres et al., 201626721795
SIRT1Cocaine↑ mRNAqPCR24 hChronicCocaine (20 mg/kg, i.p.) for 7 daysFerguson et al., 201324107942
SIRT1Cocaine↑ ProteinWB24 hChronicCocaine (20 mg/kg, i.p.) for 7 daysFerguson et al., 201324107942
SIRT1Cocaine↓ SIRT1 binding to numerous promotersChIP-SIRT, 125 increase and 488 decrease in promoter after cocaine24 hChronicCocaine (20 mg/kg, i.p.) for 7 daysFerguson et al., 201525698746
SIRT1Cocaine↓ SIRT1 binding to numerous promotersChIP-SIRT, 8949 decrease and 2245 increase after cociane24 hChronicCocaine (20 mg/kg, i.p.) for 7 daysFerguson et al., 201525698746
SIRT1Cocaine↓ SIRT1 binding to numerous promoters24 hChronicCocaine (20 mg/kg, i.p.) for 7 daysFerguson et al., 201525698746
SIRT1Cocaine↑ mRNAqPCR24 hChronicCocaine (20 mg/kg, i.p.) for 7 daysRenthal et al., 200919447090
SIRT1Cocaine↑ SIRT1 activity24 hChronicCocaine (20 mg/kg, i.p.) for 7 daysRenthal et al., 200919447090
SIRT1Cocaine↑ mRNAqPCR4 hChronicCocaine (20 mg/kg, i.p.) for 7 daysFerguson et al., 201324107942
SIRT1Cocaine↑ mRNAqPCR5 daysChronicCocaine (20 mg/kg, i.p.) for 7 daysFerguson et al., 201324107942
SIRT1Morphine↑ mRNAqPCR24 hChronicMorphine (20 mg/kg, i.p.) for 7 daysFerguson et al., 201324107942
SIRT1Morphine↑ ProteinWB24 hChronicMorphine (20 mg/kg, i.p.) for 7 daysFerguson et al., 201324107942
SIRT1Morphine↑ mRNAqPCR5 daysChronicMorphine (20 mg/kg, i.p.) for 7 daysFerguson et al., 201324107942
SIRT2Cocaine↑ SIRT2 activity24 hChronicCocaine (20 mg/kg, i.p.) for 7 daysRenthal et al., 200919447090
SIRT2Cocaine↑ mRNAqPCR24 hChronicCocaine (20 mg/kg, i.p.) for 7 daysFerguson et al., 201324107942
SIRT2Cocaine↑ ProteinWB24 hChronicCocaine (20 mg/kg, i.p.) for 7 daysFerguson et al., 201324107942
SIRT2Cocaine↑ mRNAqPCR24 hChronicCocaine (20 mg/kg, i.p.) for 7 daysRenthal et al., 200919447090
SIRT2Cocaine↑ mRNAqPCR4 hChronicCocaine (20 mg/kg, i.p.) for 7 daysFerguson et al., 201324107942
CBPCocaine↑ CBP binding on cfos promoterChIP-qPCR1 hAcuteCocaine (10 mg/kg, i.p.)Malvaez et al., 201122114264
CBPCocaine↑ CBP binding on cfos promoterChIP-qPCR1 hChronicCocaine (10 mg/kg, i.p.), for 5 daysMalvaez et al., 201122114264
CBPEthanol↓ mRNAqPCR18 hDrinkingChronic intermittent access two bottle choice 20% alcohol drinking 3 days per week for 4 weeksSharma et al., 202134837399
Myst3Ethanol↑ mRNA in high drinkers6 hDrinkingEthanol drinking sessions (4 drinking and 4 days of abstinence, repeated four times)Wolstenholme et al., 201121698166
Atf-2Methamphe
tamine
↑ proteinWB1 hAcuteMETH (20 mg/kg, i.p.)Martin et al., 201222470541
Atf-2Methamphe
tamine
↑ proteinWB16 hAcuteMETH (20 mg/kg, i.p.)Martin et al., 201222470541
Atf-2Methamphe
tamine
↑ proteinWB2 hAcuteMETH (20 mg/kg, i.p.)Martin et al., 201222470541
Atf-2Methamphe
tamine
↑ proteinWB4 hrsAcuteMETH (20 mg/kg, i.p.)Martin et al., 201222470541
Atf-2Methamphe
tamine
↑ proteinWB8 hrsAcuteMETH (20 mg/kg, i.p.)Martin et al., 201222470541
G9a/Ehmt2Cocaine↑ binding at Cdk5, p65/NFkB, FosB, promotersChIP-qPCR1 hrsAcuteCocaine (20 mg/kg, i.p.)Maze et al., 201020056891
G9a/Ehmt2Cocaine↓ binding at LIMK promotersChIP-qPCR1 hAcuteCocaine (20 mg/kg, i.p.)Maze et al., 201020056891
G9a/Ehmt2Cocaine↓ mRNA in Drd1qPCR2 hChronicCocaine (20 mg/kg, i.p.) for 8 daysMaze et al., 201424584053
G9a/Ehmt2Cocaine↓ mRNA in Drd2qPCR2 hChronicCocaine (20 mg/kg, i.p.) for 8 daysMaze et al., 201424584053
G9a/Ehmt2Cocaine↓ ProteinWB24 hChronicCocaine (20 mg/kg, i.p.) for 7 daysCovington et al., 201121867882
G9a/Ehmt2Cocaine↓ mRNAqPCR24 hChronicCocaine (20 mg/kg, i.p.) for 7 daysKennedy et al., 201323475113
G9a/Ehmt2Cocaine↓ binding at Cdk5, p65/NFkB, Arc, FosB, LIMK, BDNF, APRT promotersChIP-qPCR24 hChronicCocaine (20 mg/kg, i.p.) for 7 daysMaze et al., 201020056891
G9a/Ehmt2Cocaine↓ mRNAqPCR24 hChronicCocaine (20 mg/kg, i.p.) for 7 daysMaze et al., 201020056891
G9a/Ehmt2Cocaine, human↓ proteinWBHumanHuman Post mortemMaze et al., 201424584053
G9a/Ehmt2Ethanol↓ proteinWB3 daysChronicChronic intermittent alcohol vapor exposureAnderson et al., 202134013595
G9a/Ehmt2Ethanol↓ mRNA in high drinkers6 hDrinkingEthanol drinking sessions (4 drinking and 4 days of abstinence, repeated four times)Wolstenholme et al., 201121698166
G9a/Ehmt2Morphine↓ mRNAqPCR24 hChronicMorphine (20 mg/kg, i.p.) for 5 daysSun et al., 2012;23197736
G9a/Ehmt2Morphine↓ mRNAqPCR24 hChronicMorphine (20 mg/kg, i.p.) for 7 daysSun et al., 2012;23197736
GLP/Ehmt1Cocaine↓ mRNA in Drd1qPCR2 hChronicCocaine (20 mg/kg, i.p.) for 8 daysMaze et al., 201424584053
GLP/Ehmt1Cocaine↓ mRNAqPCR24 hChronicCocaine (20 mg/kg, i.p.) for 7 daysMaze et al., 201020056891
Suv39h1 (KMT1A)Amphetamine↑ mRNAqPCR5 daysChronicAmphetamine (4 mg/kg, i.p.) for 7 daysRenthal et al., 200918632938
Mll1Methamphe
tamine
↑ mRNAqPCR1.5 hAcuteMETH with CPP conditiningAguilar-Valles et al., 201424183790
Setd6Ethanol↓ mRNAqPCR0.5 hAcuteEthanol (2 g/kg, i.p), challenge at 17 daysBotia et al., 201223110077
Setd6Ethanol↓ mRNA, sensitized animalsqPCR0.5 hChronicEthanol (2 g/kg, i.p), for 10 days + Ethanol challenge at 17 daysBotia et al., 201223110077
Smyd3Ethanol↓ mRNAqPCR0.5 hAcuteEthanol (2 g/kg, i.p), challenge at 17 daysBotia et al., 201223110077
Smyd3Ethanol↓ mRNA, sensitized animalsqPCR0.5 hChronicEthanol (2 g/kg, i.p), for 10 days + Ethanol challenge at 17 daysBotia et al., 201223110077
PRMT1Cocaine↑ activity0.5 hAcuteCocaine (20 mg/kg) with 3 CPP conditioningLi Y. et al., 201526377474
PRMT1Cocaine↑ mRNAqPCR1 hAcuteCocaine (20 mg/kg, i.p.)Li Y. et al., 201526377474
PRMT1Cocaine↓ mRNAqPCR24 hAcuteCocaine (20 mg/kg, i.p.)Damez-Werno et al., 201627506785
PRMT1Cocaine↓ mRNAqPCR24 hChronicCocaine (20 mg/kg, i.p.) for 7 daysDamez-Werno et al., 201627506785
PRMT1Cocaine↑ mRNAqPCR24 hChronicCocaine (20 mg/kg, i.p.) for 7 daysLi Y. et al., 201526377474
PRMT1Cocaine↑ proteinWB24 hChronicCocaine (20 mg/kg, i.p.) for 7 daysLi Y. et al., 201526377474
PRMT1Cocaine↑ mRNAqPCR24 hSACocaine SALi Y. et al., 201526377474
PRMT1Cocaine↑ proteinWB24 hSACocaine SALi Y. et al., 201526377474
PRMT10Ethanol↑ mRNANanoString analysis3 weeksChronicChronic intermittent alcohol vapor exposureJohnstone et al., 202131373129
PRMT2Cocaine↓ mRNAqPCR24 hChronicCocaine (20 mg/kg, i.p.) for 7 daysDamez-Werno et al., 201627506785
PRMT4Ethanol↓ mRNA, withdrawal 3 weeksNanoString analysis3 weeksChronicChronic intermittent alcohol vapor exposureJohnstone et al., 202131373129
PRMT5Cocaine↓ mRNAqPCR24 hChronicCocaine (20 mg/kg, i.p.) for 7 daysDamez-Werno et al., 201627506785
PRMT5Ethanol↓ mRNAqPCR0.5 hAcuteEthanol (2 g/kg, i.p), challenge at 17 daysBotia et al., 201223110077
PRMT5Ethanol↓ mRNA, sensitized animalsqPCR0.5 hChronicEthanol (2 g/kg, i.p), for 10 days + Ethanol challenge at 17 daysBotia et al., 201223110077
PRMT6Cocaine↓ mRNAqPCR24 hChronicCocaine (20 mg/kg, i.p.) for 7 daysDamez-Werno et al., 201627506785
PRMT6Cocaine↓ mRNAqPCR24 hChronicCocaine (20 mg/kg, i.p.) for 7 daysDamez-Werno et al., 201627506785
PRMT6Cocaine↓ ProteinWB24 hChronicCocaine (20 mg/kg, i.p.) for 7 daysDamez-Werno et al., 201627506785
PRMT6Cocaine↓ mRNAqPCR24 hChronicCocaine (20 mg/kg, i.p.) for 7 daysLi Y. et al., 201526377474
PRMT6Cocaine↓ mRNAqPCR28 daysChronicCocaine (20 mg/kg, i.p.) for 7 daysDamez-Werno et al., 201627506785
PRMT6Cocaine↓ ProteinWB7 daysSACocaine SADamez-Werno et al., 201627506785
PRMT6Cocaine, human↓ mRNAqPCRHumanHuman Post mortemDamez-Werno et al., 201627506785
PRMT6Ethanol↓ mRNAqPCR0.5 hAcuteEthanol (2 g/kg, i.p), challenge at 17 daysBotia et al., 201223110077
PRMT6Ethanol↓ mRNA, sensitized animalsqPCR0.5 hChronicEthanol (2 g/kg, i.p), for 10 days + Ethanol challenge at 17 daysBotia et al., 201223110077
PRMT7Ethanol↓ mRNAqPCR0.5 hAcuteEthanol (2 g/kg, i.p), challenge at 17 daysBotia et al., 201223110077
PRMT7Ethanol↓ mRNA, sensitized animalsqPCR0.5 hChronicEthanol (2 g/kg, i.p), for 10 days + Ethanol challenge at 17 daysBotia et al., 201223110077
PRMT8Cocaine↓ mRNAqPCR24 hChronicCocaine (20 mg/kg, i.p.) for 7 daysDamez-Werno et al., 201627506785
PRMT9Cocaine↓ mRNAqPCR24 hChronicCocaine (20 mg/kg, i.p.) for 7 daysDamez-Werno et al., 201627506785
KDM6BEthanol↑ proteinWB3 weeksChronicChronic intermittent alcohol vapor exposureJohnstone et al., 202131373129
KDM6BEthanol↓ mRNAqPCR3 weeksChronicChronic intermittent alcohol vapor exposureJohnstone et al., 202131373129
KDM6BEthanol, human↑ mRNA - humans with AUDqPCRHumanJohnstone et al., 202131373129

Effects of drug exposure on epigenetic regulators in the NAc.

Effects of Drugs on Epigenetic Regulators in the Nucleus Accumbens in Humans

Notably, though we mainly only review rodent studies, several important pieces of evidence in post-mortem human NAc studies demonstrate that drug exposure induces alteration of many epigenetic regulators for histone acetylation and histone methylation. HDAC5 mRNA is downregulated in the NAc of people that use heroin (Egervari et al., 2017). In addition, the methyltransferases G9a and PRMT6 are downregulated in post-mortem NAc tissue from people that take cocaine (Maze et al., 2014; Damez-Werno et al., 2016). Finally, the histone lysine-specific demethylase KDM6B is upregulated in people diagnosed with alcohol use disorder (Johnstone et al., 2021). This down-regulation of methyltransferases and upregulation of demethylases may produce some similar changes in histone marks in the NAc of humans with SUD as compared to rodent models of SUD (Tables 1, 2), but these have not been closely examined yet.

Effects of Addictive Drugs on Epigenetic Regulators in the Nucleus Accumbens in Rodent Models

As shown in Table 3 there are many known candidates that are regulated by drug exposure in the NAc.

Histone Deacetylase Proteins

Many histone deacetylase proteins (HDACs), including Class I (HDAC1, 2, 3, and 8), Class IIa (HDAC4, 5, 7, and 9), Class IIb (HDAC6 and 10), Class III (SirtI and II), and Class IV (HDAC11), are regulated by drug exposure as detailed below.

Class I Histone Deacetylase Proteins (HDAC1, 2, 3, and 8)

HDAC1 protein expression decreases after acute non-contingent methamphetamine exposure for at least 1-16 h (Martin et al., 2012). In contrast, chronic non-contingent cocaine exposure increases the enrichment of HDAC1 on G9a and GLP promoters at 4 hrs after the last drug exposure (Kennedy et al., 2013). Chronic non-contingent amphetamine exposure for consecutive 7 days increases HDAC1 enrichment on the cfos promoter at 5 days after the last exposure (Renthal et al., 2008). HDAC2 expression increases after acute non-contingent exposure to nicotine and methamphetamine, chronic non-contingent exposure to ethanol, and contingent self-administered cocaine (Host et al., 2011; Martin et al., 2012; Faillace et al., 2015; Torres et al., 2015; Sharma et al., 2021). HDAC3 expression and binding to some promoter regions decreases after acute non-contingent exposure to cocaine and methamphetamine (Rogge et al., 2013; Torres et al., 2016). Like HDAC2, chronic exposure to non-contingent cocaine increases HDAC3 expression and binding to some promoters (Campbell et al., 2021). Finally, HDAC8 expression decreases after acute non-contingent methamphetamine exposure (Torres et al., 2016). These data demonstrate that there are distinct effects of different drugs on the expression of class I HDACs, and that both contingent and non-contingent administration can alter HDACs.

Class IIa Histone Deacetylase Proteins (HDAC4, 5, 7, and 9)

Class IIa HDACs are also regulated by drug exposure. HDAC4 expression decreases after acute non-contingent methamphetamine exposure (Torres et al., 2016). Contingent ethanol drinking in rodents increases HDAC4 mRNA expression and decreases protein expression (Griffin et al., 2017; Pozhidayeva et al., 2020). HDAC5 decreases after non-contingent cocaine conditioned place preference conditioning (Rogge et al., 2013) and after contingent chronic ethanol exposure (Pozhidayeva et al., 2020). As noted above, HDAC5 mRNA is similarly downregulated in the NAc of people that use heroin (Egervari et al., 2017). HDAC7 expression decreases for at least 1-8 h following an acute methamphetamine exposure, like HDAC4 (Torres et al., 2016). HDAC9 expression decreases in rodents subjected to chronic non-contingent ethanol exposure after a withdrawal of 3 weeks (Johnstone et al., 2021).

Class IIb Histone Deacetylase Proteins (HDAC6 and 10)

HDAC6 mRNA increases after acute, non-contingent methamphetamine from 1-8 h after the exposure (Torres et al., 2016).

Class III (SirtI and II)

Increased Sirt1 expression and activity is observed at both 4-24 h and 5 days after chronic non-contingent cocaine exposure. Similarly, Sirt2 expression and activity increases after chronic non-contingent cocaine exposure (Renthal et al., 2009; Ferguson et al., 2015). Also, ChIP-seq with Sirt1 analysis identified changes in Sirt1 enrichment on some promoter regions after chronic non-contingent cocaine exposure (Ferguson et al., 2015).

Class IV Histone Deacetylase Proteins

HDAC11 mRNA expression changes after exposure to contingent cocaine self-administration (Host et al., 2011), non-contingent methamphetamine (Torres et al., 2016), and non-contingent ethanol exposure (Botia et al., 2012). In these studies, both acute non-contingent ethanol and chronic ethanol exposure decreases HDAC11 mRNA. Similarly, acute methamphetamine decreases mRNA expression from 1 to 8 hrs. In contrast, contingent cocaine self-administration increases HDAC11 expression at 2 hrs after the last drug exposure.

Histone Acetyltransferases

Histone acetyltransferases (HATs) are also regulated by drug exposure. Both acute and chronic non-contingent cocaine exposure increases the enrichment of Creb-binding protein (CBP) on a specific promoter (Malvaez et al., 2011) (see Table 3 for details). Also, chronic contingent ethanol exposure decreases CBP mRNA expression (Sharma et al., 2021). Finally, lysine acetyltransferase 6A, KAT6A (also known as Myst3) mRNA increases after contingent chronic exposure to ethanol (Wolstenholme et al., 2011) and Atf-2 increases following a non-contingent methamphetamine exposure (Martin et al., 2012).

Histone Lysine Methyltransferases

The histone methyltransferase G9a regulates several histone marks including H3K9me2 and G9a expression in the NAc is reduced by chronic exposure to non-contingent cocaine (Maze et al., 2014), non-contingent morphine (Sun et al., 2012), and both contingent/non-contingent alcohol models (Wolstenholme et al., 2011; Anderson et al., 2021). Consistent with decreasing G9a protein expression after chronic cocaine exposure, G9a enrichment on several gene promoters increase at 1 h after acute non-contingent cocaine exposure and decrease at 24 h after chronic cocaine exposure (Maze et al., 2010). As mentioned above, G9a is also downregulated in humans that use cocaine (Maze et al., 2014). Of note, another histone methyltransferase called G9a-like protein (GLP, also called EHMT1) also decreases following non-contingent cocaine exposure (Maze et al., 2010, 2014). Also, the lysine methyltransferase (KMT) KMT1A (also known as Suv39h1) increases after 7 days of non-contingent amphetamine exposure (Renthal et al., 2008). In addition, KMT2a (also known as Mll1) increases after non-contingent methamphetamine conditioned place preference conditioning (Aguilar-Valles et al., 2014), and the KMTs Setd6 and Smyd3 decrease following both acute and chronic exposure to non-contingent ethanol (Botia et al., 2012).

Protein Arginine Methyltransferases

Protein arginine methyltransferases (PRMTs) like PRMT1 to PRMT6 and PRMT8 to PRMT10 are also altered after drug exposure. PRMT1 was initially reported to increase expression and activity after acute and chronic non-contingent exposure to cocaine, and following contingent cocaine self-administration (Li Y. et al., 2015). In contrast, a later paper reported that PRMT1 decreases after acute and chronic non-contingent cocaine exposure (Damez-Werno et al., 2016), so there is some disagreement in this area. PRMT2, PRMT5, PRMT6, PRMT8, and PRMT9 decrease following chronic non-contingent cocaine exposure (Li Y. et al., 2015; Damez-Werno et al., 2016). PRMT6 also decreases 7 days after the last contingent cocaine self-administration and 28 days after the last non-contingent cocaine exposure (Damez-Werno et al., 2016), suggesting this may be a long-lasting change in the NAc. As noted above, PRMT6 mRNA is similarly downregulated in post-mortem samples from people that take cocaine. PRMT5, PRMT6, and PRMT7 mRNA expression decreases 30 min after a non-contingent ethanol challenge at 17 days after 10 days of chronic non-contingent ethanol exposure (Botia et al., 2012). Finally, PRMT4 decreases at least 3 weeks after chronic intermittent alcohol vapor exposure (Johnstone et al., 2021).

Other Epigenetic Regulators

In addition, other epigenetic regulators are also altered by drugs exposure like the lysine demethylase (KDM) KDM6B. KDM6B mRNA and protein expression were increase and decrease, respectively, at 3 weeks after chronic exposure to non-contingent ethanol (Johnstone et al., 2021). As noted above, KDM6B is similarly upregulated in humans with AUD.

Activity, Localization, Phosphorylation, and Binding Changes of Epigenetic Regulators

Most of the previously mentioned studies measure RNA or protein levels, however some have shown that drug exposure can alter other aspects of protein regulation like nuclear versus cytoplasmic localization of HDAC4 and HDAC5 (Renthal et al., 2009; Taniguchi et al., 2012; Penrod et al., 2018), phosphorylation (Renthal et al., 2009; Taniguchi et al., 2012; Penrod et al., 2018), or their binding activity to genes (Renthal et al., 2009; Maze et al., 2010; Levine et al., 2011; Malvaez et al., 2011; Kennedy et al., 2013; Rogge et al., 2013; Ferguson et al., 2015; Li Y. et al., 2015; Torres et al., 2015; Campbell et al., 2021). These changes suggest that simply examining the up- or -down regulation of mRNA and/or protein levels may be insufficient to understand how epigenetic regulators are altered by addictive drugs.

Conclusion

Many epigenetic regulator proteins are altered by drug exposure. These changes have been observed in rodent studies and human post-mortem studies as well. These findings suggest that at least some preclinical findings translate to the clinic. Finally, this suggests that treatments that can alter drug-related behaviors in preclinical studies may be beneficial clinically to treat SUD.

Effects of Systemically Injected Inhibitors of Epigenetic Regulators on Drug-Related Behaviors

Many studies have altered drug-related behaviors in preclinical rodent studies by systemic or i.c.v. administration of inhibitors/activators of epigenetic proteins. As shown in Table 4, these studies have produced mixed results. The same or similar inhibitor compounds sometimes increase or decrease drug-related behaviors depending on the drug used or the behavioral procedure. We have organized Table 4 based on the type of inhibitor used and described the epigenetic target, drugs, behavioral model, and whether it was reported to increase or decrease drug-taking or drug-seeking behavior.

TABLE 4

Epigenetic TargetDrugManipulationBehaviorBehavioral EffectReferencesPMID
HDACsHeroinNaBut, non-specific inhbitor, i.c.v.SA↑ Heroin SA primed-reinstatement, 12 hrs before Heroin primeChen et al., 201627742468
HDACsEthanolNaBut, non-specific inhbitor, i.c.v.SA↓ Ethanol SA in only dependent ratsSimon-O’Brien et al., 201525041570
HDACsCocaineNaBut, non-specific inhbitor, systemicCPP↑ Cocaine CPPItzhak et al., 201323567105
HDACsCocaineNaBut, non-specific inhbitor, systemicCPP↑ Cocaine CPP extinctionMalvaez et al., 201019765687
HDACsMorphineNaBut, non-specific inhbitor, systemicCPP↑ Morphine CPPSanchis-Segura et al., 200919727068
HDACsCocaineNaBut, non-specific inhbitor, systemicCPP↓ Cocaine CPP ExtinctionItzhak et al., 201323567105
HDACsCocaineNaBut, non-specific inhbitor, systemicCPP↓ Cocaine CPP primed reinstatementMalvaez et al., 201019765687
HDACsNicotineNaBut, non-specific inhbitor, systemicCPP↓ Nicotine CPPPastor et al., 201121166804
HDACsAmphetamineNaBut, non-specific inhbitor, systemicLocomotor↑ Amphetamine locomotor sensitizationKalda et al., 200717477979
HDACsCocaineNaBut, non-specific inhbitor, systemicLocomotor↑ Cocaine locomotor activity and sensitizationKumar et al., 200516242410
HDACsMorphineNaBut, non-specific inhbitor, systemicLocomotor↑ Morphine sensitizationSanchis-Segura et al., 200919727068
HDACsEthanolNaBut, non-specific inhbitor, systemicLocomotor↓ Ethanol locomotor sensitizationLegastelois et al., 201323488934
HDACsCocaineNaBut, non-specific inhbitor, systemicSA↑ Cocaine SASun et al., 200818599214
HDACsHeroinNaBut, non-specific inhbitor, systemicSA↑ Heroin SA primed-reinstatement, 12 hrs before Heroin primeChen et al., 201627742468
HDACsCocaineNaBut, non-specific inhbitor, systemicSA↓ Cocaine SA reinstatement (cue + cocaine combination)Romieu et al., 201121886555
HDACsEthanolNaBut, non-specific inhbitor, systemicSA↓ Ethanol SA in only dependent ratsSimon-O’Brien et al., 201525041570
HDACsEthanolTSA, non-specific inhbitor, systemicAnxiety↓ Ethanol withdrawal-induced anxietyPandey et al., 200818385331
HDACsEthanolTSA, non-specific inhbitor, systemicDrinking↑ Two-bottle Ethanol intakeWolstenholme et al., 201121698166
HDACsEthanolTSA, non-specific inhbitor, systemicDrinking↓ Ethanol consumptionSakharkar et al., 201424528596
HDACsEthanolTSA, non-specific inhbitor, systemicDrinking↓ Ethanol intake (drinking in the dark)Warnault et al., 201323423140
HDACsCocaineTSA, non-specific inhbitor, systemicCPP↑ Cocaine CPPKumar et al., 200516242410
HDACsCocaineTSA, non-specific inhbitor, systemicLocomotor↓ Cocaine locomotor sensitizationRomieu et al., 200818799668
HDACsAmphetamineTSA, non-specific inhbitor, systemicSA↓ Amphetamine SA cue-induced reinstatement in socially isolated ratsArndt et al., 201931343201
HDACsAmphetamineTSA, non-specific inhbitor, systemicSA↓ Amphetamine SA cue-reinstatement in socialy isolated ratsArndt et al., 201931343201
HDACsCocaineTSA, non-specific inhbitor, systemicSA↓ Cocaine SA intakeHost et al., 201020132486
HDACsCocaineTSA, non-specific inhbitor, systemicSA↓ Cocaine SA intake and motivationRomieu et al., 200818799668
HDACsCocainePhenylbutyrate, non-specific inhbitor, systemicSA↓ Cocaine SA intakeRomieu et al., 200818799668
HDACsCocaineDepudecin, non-specific inhbitor, systemicSA↓ Cocaine SA motivationRomieu et al., 200818799668
HDACs (class I and II)EthanolVPA, selective inhibitor, systemicDrinking↓ Ethanol consumption and preference in 2-bottle choiceAl Ameri et al., 201425108044
HDACs (class I and II)EthanolVPA, selective inhibitor, systemicCPP↓ Ethanol CPPAl Ameri et al., 201425108044
HDACs (class I and II)AmphetamineVPA, selective inhibitor, systemicLocomotor↑ Amphetamine locomotor sensitizationKalda et al., 200717477979
HDACs (class I and II)EthanolSAHA, selective inhibitor, systemicDrinking↓ Ethanol intake (drinking in the dark), but not saccharinWarnault et al., 201323423140
HDACs (class I and II)CocaineSAHA, selective inhibitor, systemicCPP↑ Cocaine CPPRenthal et al., 200717988634
HDACs (class I and II)MorphineSAHA, selective inhibitor, systemicCPP↑ Morphine CPP extinctionSaberian et al., 202134302880
HDACs (class I and II)MorphineSAHA, selective inhibitor, systemicCPP↓ Morphine primed-reinstatement in CPPSaberian et al., 202134302880
HDACs (class I and II)EthanolSAHA, selective inhibitor, systemicSA/Drinking↓ Ethanol SA presses and intake, but not sucroseWarnault et al., 201323423140
HDACs (class I and II)EthanolSAHA, selective inhibitor, systemicSA/Drinking↓ Ethanol drug-seeking during EXT training, but not sucroseWarnault et al., 201323423140
HDACs (class I)EthanolMS275, selective inhibitior, i.c.v.Drinking↓ Ethanol consumption, lever presses, motivation, ↓ relapseJeanblanc et al., 201525762717
HDACs (class I)EthanolMS275, selective inhibitior, systemicDrinking↓ Ethanol intake (drinking in the dark)Warnault et al., 201323423140
HDACs (class II)CocaineMC1568, inhibitor, systemicSA↑ Cocaine SA motivation and punishment resistanceGriffin et al., 201729109977
HDAC1 and HDAC2AmphetamineCpd-60, selective inhibitior, systemicLocomotor↓ Amphetamine locomotionSchroeder et al., 201323967191
HDAC3CocaineRGFP966, selective inhibitor, systemicCPP↑ Cocaine CPP extinctionMalvaez et al., 201323297220
HDAC3CocaineRGFP966, selective inhibitor, systemicCPP↓ Cocaine CPP reinstatementMalvaez et al., 201323297220
HDAC3CocaineRGFP966, selective inhibitor, systemicSA↓ Cocaine SA reinstatementHitchcock et al., 201930488346
HDAC4/5EthanolLMK235, HDAC4/5 inhibitor, systemicDrinking↓ Ethanol binge-like drinkingPozhidayeva et al., 202032085427
HDACsMorphineTheophylline, selective activator, systemicCPP↓ Morphine CPP extinctionSaberian et al., 202134302880
SIRTsCocaineResveratrol, agoinst, systemicCPP↑ Cocaine CPPRenthal et al., 200919447090
G9aEthanolUNC0642, selective inhibitor, systemicDrinking↓ stress-escalated Ethanol drinkingAnderson et al., 202134013595

Effects of systemic inhibitors of epigenetic regulators on drug-related behaviors.

Histone Deacetylase Protein Activators/inhibitors

Many different compounds that alter HDAC activity have been injected systemically to study their effects on drug-related behaviors.

Histone Deacetylase Protein Inhibitor: Sodium Butyrate

The non-selective HDAC inhibitor sodium butyrate (NaBut) has been shown to alter many drug-related behaviors, but can produce mixed results. For instance, NaBut increases non-contingent psychostimulant- and morphine-induced locomotor sensitization, but in contrast decreases ethanol-induced locomotor sensitization (Kumar et al., 2005; Kalda et al., 2007; Sanchis-Segura et al., 2009; Legastelois et al., 2013). In addition, NaBut increases cocaine and morphine conditioned place preference (CPP) (Sanchis-Segura et al., 2009; Itzhak et al., 2013) and decreases cocaine CPP extinction (Itzhak et al., 2013) in some papers. However, there is some disagreement as other studies show that NaBut increases cocaine CPP extinction (Malvaez et al., 2010), reduces primed reinstatement in cocaine CPP (Malvaez et al., 2010), and decreased nicotine CPP (Pastor et al., 2011). The effects of NaBut administration are thus inconsistent between these studies on non-contingent drug-related behaviors.

The effects of NaBut on contingent self-administration behaviors are also inconsistent as some papers report that NaBut increases cocaine self-administration and increases heroin prime-induced reinstatement (Sun et al., 2008; Chen et al., 2016), but others report it decreases reinstatement to cocaine-seeking and decreases alcohol drinking (Romieu et al., 2011; Simon-O’Brien et al., 2015). These discrepancies could be due to the non-selective nature of NaBut or differences in experimental design.

Histone Deacetylase Protein Inhibitor: Trichostatin A

The non-selective HDAC inhibitor trichostatin A (TSA) also alters drug-related behaviors, but not all studies are consistent. TSA increases cocaine CPP (Kumar et al., 2005) and also increases contingent ethanol intake (Wolstenholme et al., 2011), however, other reports suggest that TSA reduces ethanol drinking (Sakharkar et al., 2014), reduces ethanol withdrawal-induced anxiety (Pandey et al., 2008), and reduces psychostimulant self-administration, sensitization, and reinstatement (Romieu et al., 2008; Host et al., 2010; Arndt et al., 2019). Again, these discrepancies could be due to the non-selective nature of TSA or differences in experimental design.

Other Histone Deacetylase Protein Inhibitors

Less well studied non-selective HDAC inhibitors like phenylbutyrate and depudecin have been shown to reduce contingent cocaine self-administration (Romieu et al., 2008).

Selective Class I and II Histone Deacetylase Protein Inhibitors

Given the many differences in studies following the use of non-selective HDAC inhibitors, more selective inhibitors that act only on a subset of HDACs have also been studied (Table 4). As described above, HDACs can be divided into several classes and Class I includes HDAC1, HDAC2, HDAC3, and HDAC8. Class II includes HDAC4-HDAC7 and HDAC9-HDAC10. Both valproic acid (VPA) and suberoylanilide hydroxamic acid (SAHA) are selective for only these classes of HDACs and not other class III and IV HDACs like SIRT1-7 and HDAC11. These two inhibitors more consistently reduce drug-related behaviors. SAHA reduces contingent ethanol intake, ethanol self-administration, ethanol-seeking (Warnault et al., 2013), and SAHA also increases extinction and reduces non-contingent CPP reinstatement to morphine (Saberian et al., 2021). Like SAHA, VPA also reduces ethanol drinking and ethanol CPP (Al Ameri et al., 2014). However, other studies report that SAHA increases cocaine CPP (Renthal et al., 2007) and VPT increases amphetamine locomotor sensitization (Kalda et al., 2007). These divergent effects could be due to these drugs acting on many different targets.

Class Selective Histone Deacetylase Protein Inhibitors

Inhibitors selective for Class I HDACs (MS275) or Class II HDACs (MC1568) have also been used to alter drug-related behaviors. Interestingly, the Class 1 inhibitor reduces ethanol drinking (Warnault et al., 2013), ethanol self-administration, and reinstatement to ethanol-seeking (Jeanblanc et al., 2015), whereas the Class II inhibitor increases the motivation for cocaine self-administration (Griffin et al., 2017) suggesting different roles for these HDAC classes.

More Selective HDAC Inhibitors

Moving from classes to specific proteins, Compound 60 is a selective inhibitor of HDAC1 and HDAC2 and reduces acute non-contingent amphetamine locomotor behavior (Schroeder et al., 2013). Also, RGFP966 is a selective inhibitor of HDAC3 and increases CPP extinction, blocks reinstatement (Malvaez et al., 2013), and also reduces reinstatement to cocaine seeking (Hitchcock et al., 2019). Finally, LMK235 is an HDAC4/HDAC5 inhibitor that reduces contingent ethanol intake (Pozhidayeva et al., 2020). In general, these reports suggest that more selective HDAC inhibitors may be more consistent in reducing cocaine-seeking and ethanol intake behaviors, though they are still understudied at this point.

Histone Deacetylase Protein Activators

Activators of HDACs have also been studied, but rarely. The HDAC activator theophylline decreases extinction to non-contingent morphine CPP and (Saberian et al., 2021) the SIRT agonist resveratrol increases non-contingent cocaine CPP (Renthal et al., 2009). Since these studies suggest that HDAC activation increases drug-related behaviors, they complement some of the HDAC inhibitor studies that show decreases in drug-related behaviors.

Histone Deacetylase Protein Inhibitor/Activator Conclusions

Examining all these HDAC inhibitor/activator studies together, it is not possible to draw a strong conclusion on their effects on behavior. This could be due to these systemically administered compounds affecting many different brain and/or body regions, but could also be due to differences in experimental design and timing of exposure.

G9a Inhibitors

The systemic G9a inhibitor UNC0642 has recently been shown to reduce stress-induced alcohol drinking (Anderson et al., 2021), suggesting other epigenetic regulators can be targeted with systemic injections as well.

Effects of Nucleus Accumbens-Specific Epigenetic Regulator Manipulations on Drug-Related Behaviors

Since systemic inhibitors likely alter many brain regions, NAc-specific manipulations are more helpful to determine the specific effect of epigenetic regulator proteins in this brain region. Many epigenetic modifiers have been targeted in a NAc-specific manner as thoroughly described in Table 5.

TABLE 5

Epigenetic TargetDrugManipulationBehaviorBehavioral EffectReferencesPMID
HDACsCocaineTSA, non-specific inhbitor, intra-NacSA↑ Cocaine SA motivationWang et al., 201020010550
HDACsCocaineTSA, non-specific inhbitor, intra-NacSA↑ Cocaine SA sensitivityWang et al., 201020010550
HDACsEthanolTSA, non-specific inhbitor, intra-NacLocomotor↑ Ethanol lomotor behaviorSprow et al., 201425130590
HDACsHeroinTSA, non-specific inhbitor, intra-NacCPP↑ Heroin CPPSheng et al., 201121734607
HDACsCocaineTSA, non-specific inhbitor, intra-NacSA↓ Cocaine SA reinstatement (cue + cocaine combination)Romieu et al., 201121886555
HDACsEthanolTSA, non-specific inhbitor, intra-NacDrinking↓ Ethanol intake (drinking in the dark)Warnault et al., 201323423140
HDACsAmphetamineVPA, inhibitor, intra-NacLocomotor↓ amphetamine locomotor sensitizationKim et al., 200818164815
HDACs (class I and II)CocaineSAHA, selective inhibitor, intra-NacCPP↑ Cocaine CPPRenthal et al., 200717988634
HDACs (class I and II)CocaineSAHA, selective inhibitor, intra-NacSA↑ Cocaine SA motivationWang et al., 201020010550
HDACs (class I and II)CocaineSAHA, selective inhibitor, intra-NacSA↑ Cocaine SA sensitivityWang et al., 201020010550
HDACs (class I)CocaineMS275, selective inhibitior, intra-NacLocomotor↓ Cocaine locomotor sensitizationKennedy et al., 201323475113
HDAC1CocaineFloxed HDAC1 mice, intra-Nac CreLocomotor↓ Cocaine locomotor sensitizationKennedy et al., 201323475113
HDAC3CocaineFloxed HDAC3 mice, intra-Nac AAV-creCPP↑ Cocaine CPP acquisitionRogge et al., 201323575859
HDAC3CocaineHDAC3 Y298H overexpression in D1CPP↑ Cocaine CPPCampbell et al., 202133602824
HDAC3CocaineHDAC3 Y298H overexpression in D1SA↓ Cocaine seeking withdrawal Day1 and Day 30Campbell et al., 202133602824
HDAC4CocaineCytoplasmic HDAC4 overexpressionCPP↑ Cocaine CPPPenrod et al., 201828635037
HDAC4CocaineFloxed HDAC4 mice, intra-Nac AAV-CreLocomotor↓ Acute cocaine locomotor activityPenrod et al., 201828635037
HDAC4CocaineFloxed HDAC4 mice, intra-Nac AAV-CreCPP↓ Cocaine CPPPenrod et al., 201828635037
HDAC4CocaineFloxed HDAC4 mice, intra-Nac AAV-CreLocomotor↓ Cocaine locomotor sensitizationPenrod et al., 201828635037
HDAC4CocaineHDAC4 overexpressionCPP↓ Cocaine CPPKumar et al., 200516242410
HDAC4CocaineHDAC4 overexpressionSA↓ Cocaine SA motivationWang et al., 201020010550
HDAC4CocaineHDAC4 overexpressionSA↓ Cocaine SA sensitivityWang et al., 201020010550
HDAC5CocaineHDAC5 constitutive KO mouseCPP↑ Cocaine CPPRenthal et al., 200717988634
HDAC5CocaineHDAC5 overexpressionCPP↓ Cocaine CPPRenthal et al., 200717988634
HDAC5CocaineNuclear HDAC5 overexpressionCPP↓ Cocaine CPPTaniguchi et al., 201222243750
HDAC5CocaineNuclear HDAC5 overexpressionCPP↓ Cocaine CPPTaniguchi et al., 201728957664
HDAC5CocaineNuclear HDAC5 overexpressionSA↓ Cocaine SA cue and primed RNTaniguchi et al., 201728957664
SIRT1CocaineFloxed SIRT1 mice, intra-Nac AAV-CreCPP↓ Cocaine CPPFerguson et al., 201324107942
SIRT1MorphineFloxed SIRT1 mice, intra-Nac AAV-CreCPP↓ Morphine CPPFerguson et al., 201324107942
SIRT1CocaineSIRT1 OverexpressionCPP↑ Cocaine CPPFerguson et al., 201324107942
SIRT1CocaineSIRT1 OverexpressionCPP↑ Morphine CPPFerguson et al., 201324107942
SIRT1CocaineSIRT1 OverexpressionLocomotor↑ Cocaine locomoter behaviorFerguson et al., 201324107942
SIRT2CocaineSIRT2 OverexpressionCPP↑ Cocaine CPPFerguson et al., 201324107942
SIRT2CocaineSIRT2 OverexpressionCPP↑ Morphine CPPFerguson et al., 201324107942
SIRTsCocaineSirtinol, antagonist, intra-NacCPP↓ Cocaine CPPRenthal et al., 200919447090
SIRTsCocaineSirtinol, antagonist, intra-NacSA↓ Cocaine SA, reduces dose responseRenthal et al., 200919447090
CBPCocaineFloxed CBP mice, intra-Nac AAV-creLocomotor↓ Acute cocaine locomotor activityMalvaez et al., 201122114264
CBPCocaineFloxed CBP mice, intra-Nac AAV-creCPP↓ Cocaine CPPMalvaez et al., 201122114264
CBPCocaineFloxed CBP mice, intra-Nac AAV-creLocomotor↓ Cocaine locomotor sensitizationMalvaez et al., 201122114264
G9a/Ehmt2CocaineBIX01294, inhibitor, intra-NacCPP↑ Cocaine CPPMaze et al., 201020056891
G9a/Ehmt2CocaineFloxed G9a mice, intra-Nac CreCPP↑ Cocaine CPPMaze et al., 201020056891
G9a/Ehmt2MorphineFloxed G9a mice, intra-Nac CreLocomotor↑ Morphine locomotor sensitizationSun et al., 201223197736
G9a/Ehmt2CocaineG9a overexpressionSA↑ Cocaine SA sensitivity, motivationAnderson et al., 2018a29217682
G9a/Ehmt2CocaineG9a overexpressionSA↑ stress-induced reinstatementAnderson et al., 2018a29217682
G9a/Ehmt2CocaineG9a overexpressionCPP↓ Cocaine CPPMaze et al., 201020056891
G9a/Ehmt2MorphineG9a overexpressionLocomotor↓ Morphine CPP and locomotor sensitizationSun et al., 201223197736
G9a/Ehmt2CocaineG9a overexpression only in D2-MSNsCPP↓ Cocaine CPPMaze et al., 201424584053
G9a/Ehmt2CocaineshRNA-mediated G9a knockdownSA↓ Cocaine drug-seeking
(context-, drug primed-, and stress-induced)
Anderson et al., 201930587852
G9a/Ehmt2CocaineshRNA-mediated G9a knockdownSA↓ Cocaine SA sensitivity, motivationAnderson et al., 201930587852
G9a/Ehmt2EthanolshRNA-mediated G9a knockdownDrinking↓ Ethanol drinking (stress-induced)Anderson et al., 202134013595
PRMT1CocaineAMI-1, selective inhibitor, intra-NacCPP↓ Cocaine CPPLi Y. et al., 201526377474
PRMT1CocaineKnockdown with LV short hairpinCPP↓ Cocaine CPPLi Y. et al., 201526377474
PRMT1CocaineMTA, selective inhibitor, intra-NacCPP↓ Cocaine CPPLi Y. et al., 201526377474
PRMT1CocaineSKLB-639, selective inhibitor, intra-NacCPP↓ Cocaine CPPLi Y. et al., 201526377474
PRMT6CocainemiRNA knockdown in D2CPP↓ Cocaine CPPDamez-Werno et al., 201627506785
PRMT6CocainePRMT6 overexpression in D2CPP↑ Cocaine CPPDamez-Werno et al., 201627506785
PRMT6CocainePRMT6 overexpression in D1CPP↓ Cocaine CPPDamez-Werno et al., 201627506785
KDM5CMethamphetaminesiRNA-mediated KDM5C knockdown in NacCPP↓ Methamphetamine CPPAguilar-Valles et al., 201424183790
Mll1MethamphetaminesiRNA-mediated Mll1 knockdown in NacCPP↓ Methamphetamine CPPAguilar-Valles et al., 201424183790

Effects of NAc-specific epigenetic regulator manipulations on drug-related behaviors.

Nucleus Accumbens-Specific Injections of Histone Deacetylase Protein Inhibitors

Several of the epigenetic inhibitors discussed above have also been injected into the NAc specifically including TSA, VPA, SAHA, and MS275. Some data suggest that injecting the non-selective HDAC inhibitors TSA and VPA into the NAc reduces drug-related behaviors like cocaine reinstatement (Romieu et al., 2011), ethanol drinking (Warnault et al., 2013), and amphetamine locomotor sensitization (Kim et al., 2008). In contrast, others suggest the opposite as TSA increases heroin CPP (Sheng et al., 2011), increases ethanol-induced locomotor behavior (Sprow et al., 2014), and increases the motivation for cocaine and cocaine sensitivity using self-administration assays (Wang et al., 2010).

The more selective HDAC inhibitors SAHA and MS275 have also been injected in the NAc. The Class I and Class II HDAC inhibitor SAHA increases CPP (Renthal et al., 2007) and increases the motivation for cocaine and cocaine sensitivity (using dose-response testing) as measured with contingent cocaine self-administration assays (Wang et al., 2010). Finally, the selective Class I HDAC inhibitor MS275 reduces locomotor sensitization when injected into the NAc (Kennedy et al., 2013). These studies demonstrate a NAc-specific effect of epigenetic regulation on drug-related behaviors, however, cannot determine which epigenetic proteins (or combination of proteins) are responsible for these effects.

Nucleus Accumbens-Specific Overexpression and/or Knockdown of Histone Deacetylase Proteins

To understand the role of individual epigenetic regulators in the NAc, many investigators have site-specifically altered the expression of a target protein and examined its effects on drug-related behaviors.

HDAC4

The first evidence of a specific functional epigenetic protein acting in the NAc was that overexpressing HDAC4 decreases cocaine CPP (Kumar et al., 2005). Later studies suggested that overexpressing HDAC4 - but not a catalytic HDAC-domain deletion mutant - reduces the motivation for cocaine as well (Wang et al., 2010), suggesting HDAC4 reduces cocaine reward-seeking behaviors. However, there are still inconsistencies as in contrast, other studies in Hdac4 NAc conditional knockout mice show HDAC4 increases drug-related behaviors like CPP and sensitization (Penrod et al., 2018).

HDAC5

Other class IIb HDAC studies show that HDAC5 blocks cocaine CPP (Renthal et al., 2007; Taniguchi et al., 2012) and reduces the reinstatement of drug-seeking behavior following cocaine self-administration (Taniguchi et al., 2017). As described above, cocaine exposure induces the dephosphorylation and nuclear accumulation of HDAC5 in a cAMP-dependent manner in D1-containing medium spiny neurons (D1-MSNs). The dephosphorylated nuclear-accumulated form of HDAC5, but not wild-type HDAC5, limits drug-related behaviors. These data suggest a MSN-cell-type dependent HDAC5 function on drug-related behaviors and in response to drug exposure.

HDAC3

The Class I HDAC, HDAC3 also alters drug-related behavior. A NAc-specific conditional knockout of HDAC3 in mice increases cocaine CPP (Rogge et al., 2013). A follow up study demonstrated a D1-MSN cell-type-specific role of HDAC3 in cocaine CPP as a mutated deacetylase activity-dead HDAC3 overexpressed only in NAc increases cocaine CPP. In the same study, the mutated deacetylase activity-dead HDAC3 also attenuates the reinstatement of drug-seeking behavior following cocaine self-administration (Campbell et al., 2021) suggesting discrepancies in the effects of epigenetic regulators on contingent vs non-contingent drug-related behaviors depending on the model used.

SIRTs

Class III HDACs (SIRTs) also regulate drug-related behavior as SIRT1 or SIRT2 overexpression increases cocaine and morphine CPP (Ferguson et al., 2013). Also, a Sirt1 conditional knockout in mice reduces cocaine and morphine CPP (Ferguson et al., 2013). Finally, a NAc-specific injection of the SIRT antagonist sirtinol reduces cocaine CPP and cocaine self-administration (Renthal et al., 2009).

Nucleus Accumbens-Specific Overexpression and/or Knockdown of HATs

Histone acetyltransferases in the NAc also function in cocaine-related behaviors as a NAc conditional knockout of CBP in mice decreases cocaine locomotor activity and cocaine CPP (Malvaez et al., 2011).

Nucleus Accumbens-Specific Overexpression and/or Knockdown of Histone Methyltransferases

Moving from acetylation to methylation, initial studies suggested that the methyltransferase G9a reduces drug-induced locomotor sensitization and drug-conditioned place preference since overexpressing G9a blocks cocaine CPP (Maze et al., 2010, 2014), morphine CPP, and morphine locomotor sensitization (Sun et al., 2012). In addition, intra-NAc administration of the G9a inhibitor BIX01294 and G9a NAc conditional knockout increases cocaine CPP (Maze et al., 2010). Also, a NAc conditional knockout of G9a increases morphine CPP and morphine locomotor sensitization (Sun et al., 2012). However, later studies using contingent cocaine self-administration as a model demonstrated that overexpressing G9a in the NAc increases cocaine sensitivity (using dose-response testing), motivation (using progressive ratio testing), and stress-induced reinstatement (Anderson et al., 2018a). A subsequent study showed that reducing NAc G9a levels via shRNA reduces the sensitivity to cocaine self-administration, motivation, and stress-induced reinstatement (Anderson et al., 2019). Together, these studies showed that G9a levels in the NAc have bi-directional effects on cocaine self-administration and cocaine-seeking behaviors (Anderson et al., 2018a,2019). In addition, reducing G9a in the NAc also blocks stress-induced ethanol drinking and this effect is recapitulated by systemic administration of UNC0642 - a selective G9a inhibitor – as mentioned above (Anderson et al., 2021). These studies again suggest that at least some differences in preclinical studies could be explained by differences in contingent vs non-contingent models.

Other Epigenetic Modifiers

Other methyltransferases like PRMT1 alter cocaine CPP as shown by PRMT1 knockdown and pharmacological inhibition studies (Li Y. et al., 2015). Also, PRMT6 overexpression in the NAc increases cocaine CPP, and miRNA-mediated knockdown reduces cocaine CPP (Damez-Werno et al., 2016). Finally, another study shows that KDM5C or Mll1 knockdown reduces methamphetamine CPP (Aguilar-Valles et al., 2014).

Conclusion

These studies and others in Table 5 demonstrate the powerful effects that epigenetic regulators can have on drug-related behaviors in pre-clinical models. However, these reports often conflict concerning the function of these NAc-specific manipulations, suggesting that differences in experimental design (like the use of contingent vs non-contingent models) can produce different behavioral effects. Still, these reports suggest that translating some of these methods into the clinic could potentially help to reduce the negative effects of substance use.

Limitations and Challenges in the Field of Epigenetics and Substance Use Disorder

Diversity of Epigenetic Modifications and Their Substrates

Despite the large amount of data on epigenetic regulation in rodent models of SUD, and the ability to alter drug-related behaviors through either systemically administered or NAc-specific manipulations, there are still many limitations and challenges for the field. Beginning with examining changes in drug-induced epigenetic modifications, we think that there is a great need for more unbiased approaches. For instance, after initial studies found changes in H3 and H4 PTMs, many subsequent studies only examined these sites with specific antibodies. While these studies often found changes, the focus on these known sites could have prevented the discovery of other important sites of regulation, especially considering the wide array of time-dependent and substance-dependent changes shown in Tables 1, 2. These biases extended to a concentrated study of just a handful of histone PTMs when there are over 100 histone PTMs, most of which have not been examined following exposure to addictive drugs. For example, there are reports on other epigenetic markers like histone phosphorylation that can be altered following cocaine (Bertran-Gonzalez et al., 2008), morphine (Ciccarelli et al., 2013), and methamphetamine use (Rotllant and Armario, 2012). In addition, poly-ADP-ribosylation of histones is altered by drug exposure (Scobie et al., 2014). Notably, two novel histone modifications, serotonylation (Farrelly et al., 2019) and dopaminylation of H3Q5 (Lepack et al., 2020), have been recently reported and could play a role in NAc-mediated drug-related behaviors. Dopaminylation of H3Q5 in the VTA is dysregulated by cocaine exposure and may alter cocaine self-administration behavior (Lepack et al., 2020) and could play a role in the NAc as well. Given the recent reports of these novel histone PTMs, it is possible that we are still missing other important PTMs too.

Some of these issues are due to technical challenges like the need for better antibodies to other PTMs. ChIP assays are limited by the available antibodies so even large “unbiased” approaches have an inherent bias based on these tools (Renthal et al., 2009; Feng et al., 2014) and truly unbiased genome wide PTMs analyses are not yet possible. In addition to examining the epigenetic modifications that influence the transcriptome, chromatin accessibility could be examined by unbiased genome-wide approaches using an Assay for Transposase-Accessible Chromatin (ATAC)-seq or DNase-seq (Fullard et al., 2018; Carullo et al., 2020; Scherma et al., 2020). These assays could be coupled with other unbiased approaches to examine the downstream effects of these targets on transcriptional changes like RNA-seq and/or microarrays to get closer to a complete picture of the effects of these epigenetic changes produced by drugs exposure. Indeed, many of the studies examined in this review did not report on transcriptomic changes and only examined histone PTMs or select gene expression changes. Finally, very little is known of the actual protein changes (and not just mRNA changes) that occur following these epigenetic manipulations and future studies should examine the functional outcomes of these epigenetic effects.

Other forms of epigenetic regulation not involving direct histone PTM regulation can also influence drug-related behaviors. Though out of the scope of this review, DNA methylation is another form of epigenetic regulation that can be altered by drug exposure for weeks after the last drug exposure. In addition, manipulating proteins associated with DNA methylation can also alter drug-related behaviors (see (Werner et al., 2021) and (Anderson et al., 2018b) for reviews). Also, other types of cellular regulation, including non-coding RNAs (ncRNA), are beginning to be understood extensively (Gu et al., 2021). For example, long ncRNAs can be regulated by cocaine at least 24 hrs after the last injection (Bu et al., 2012). Also, microRNAs are regulated by cocaine, heroin, and methamphetamine in the NAc (Eipper-Mains et al., 2011; Su et al., 2019; Dash et al., 2020; Yang et al., 2020; Li et al., 2021; Xu et al., 2021) and the dorsal striatum (Hollander et al., 2010; Im et al., 2010). Finally, small nucleolar RNAs (snoRNAs) are also regulated by cocaine and knockdown of MBII-52 attenuates cocaine CPP (Chen et al., 2014). Taking a broader look at epigenetic regulation of these RNA subtypes could help us determine which epigenetic mechanisms should be targeted to reduce the negative effects of SUD in humans.

Cell Type Specific Epigenetic Regulations

Another major limitation of almost all studies to date is that they do not separate different cellular populations like neurons vs glia. Drug-induced molecular and synaptic plasticity alterations occur in specific cell types to drive behavioral changes (Lobo et al., 2010; Pascoli et al., 2011; Maze et al., 2014; Campbell et al., 2021), but these are often overlooked in whole NAc tissue punches. Not only are glia often included in these epigenetic assays, but neurons that may not be involved in drug-related behaviors are also included. Only small populations of neurons that have been activated during drug-related learning, called engrams, seem to be important for various drug-related behaviors (Koya et al., 2009; Cruz et al., 2014; Hsiang et al., 2014). In contrast, most epigenetic and molecular studies examine whole tissue in the NAc following drug exposure. This means that all cells are being studied in these analyses including dopamine receptor D1 or D2-containing medium spiny neurons (D1- or D2-MSNs), interneurons, glial cells, microglia, and even some amount of blood vessel and blood cells. This hodgepodge of cells may be limiting our ability to detect the specific changes relating to SUD. Perhaps the subset of important cells that drive addictive behavior do retain a distinct histone methylation or acetylation signature, but this is diluted by other cells that return to baseline thus limiting our ability to detect lasting changes that are still present.

Reducing this signal to noise ratio is possible thanks to technologies like cre-driven gene expression or single cell RNA-seq (Macaulay et al., 2017). Several studies have examined differences in D1- and D2-MSN cell type specific regulation of epigenetic mechanisms. These studies suggest distinct epigenetic regulation in specific cell types. For instance, HDAC3, G9a, and PRMT6 have unique roles in D1 vs D2-MSN cell type specific manner (Maze et al., 2014; Damez-Werno et al., 2016; Campbell et al., 2021). Also, cocaine increased H3 phosphorylation only in D1 cells according to one report (Bertran-Gonzalez et al., 2008). Using a combination of cell-type specific transcriptomic analyses and cre-dependent cell lines will be able to further elucidate the role of epigenetic regulation in D1- and D2-MSNs in SUD. Technologies like Fos-Targeted Recombination in Active Population (TRAP) and ArcTRAP allow for examining groups of cells that are regulated together through activity. This technique was recently used and found that despite no overall changes in dorsal striatum HDAC4 and HDAC5 mRNA levels, these transcripts were altered in FOS-positive neurons following prolonged methamphetamine self-administration withdrawal (Li X. et al., 2015). These current advanced technologies enable us to examine transcription and open chromatin status at the single-cell or single-nucleus level. Combining these techniques with RNA-seq, ATAC-seq, or ChIP-seq could also provide data on epigenetic changes at the single-cell level (Rotem et al., 2015). These powerful techniques could help to determine more specific roles of epigenetic regulation caused by exposure to addictive drugs.

Effects of Contingent and Non-contingent Drugs Exposure

Some differences discussed in this review may be due to issues in the rodent models used in these studies. As mentioned above, rodent models can be broadly separated into two classes: (1) experimenter administered (non-contingent) models, including CPP, locomotor sensitization, and alcohol vapor exposure where the rodents have no choice in drug exposure or (2) self-administration (contingent) models that allow the rodents more choice over when to take drugs. These assays include alcohol drinking (2-bottle choice, drinking-in-the-dark) and drug self-administration. Sometimes, these contingent and non-contingent experimental models indicate a similar role of epigenetic regulators in the development of drug reward-conditioned behaviors. For example, HDAC5 has similar roles on drug-related behavior following both non-contingent cocaine CPP and contingent reinstatement of cocaine-seeking behaviors after cocaine SA (Taniguchi et al., 2017). In addition, HDAC4 overexpression in the NAc decreases cocaine intake and reduces motivation in the progressive ratio schedule in a contingent self-administration model (Wang et al., 2010) and also decreases non-contingent cocaine CPP (Kumar et al., 2005). In contrast, in a later study, Hdac4 NAc conditional knockout mice exhibited decreases in cocaine-induced locomotor activity, sensitization, and cocaine CPP in non-contingent experiments (Penrod et al., 2018). Disagreements in the literature like these examples are often found and can lead to very different interpretations. For example, G9a NAc conditional knockout mice exhibited increases in cocaine CPP and overexpressing G9a decreases cocaine CPP suggesting G9a reduces the cocaine-induced behavioral plasticity using non-contingent models (Maze et al., 2010). However, in a contingent cocaine self-administration model, G9a overexpression increases sensitivity in dose-response test, motivation in progressive ratio testing, and stress-induced reinstatement, suggesting that G9a increases cocaine-related behaviors (Anderson et al., 2018a). Since behavioral differences are observed using similar manipulations of epigenetic regulators, it is important to examine the effects of epigenetic manipulations in a variety of behavioral tasks to find those that may be more likely to translate to humans.

Future Directions and Conclusion

As shown above, we now know drug exposure regulates histone marks and epigenetic regulators. Most of these changes appear to be very short-lived, but some can be long-lasting (at least a month) especially when examining changes at specific promoters (Damez-Werno et al., 2012, 2016; Tomasiewicz et al., 2012; Flagel et al., 2016; Carpenter et al., 2020; Johnstone et al., 2021). However, we still do not understand the mechanisms that promote some changes and not others, and it is often difficult to tell if these changes are functional and whether they are addiction-promoting or counter adaptive protective mechanisms (Anderson et al., 2018a). Fortunately, new technologies are being developed that allow for the selective targeting of specific genomic loci (Heller et al., 2014, 2016; Hamilton et al., 2018), these cutting-edge tools allow for epigenetic regulation of a single gene and allow very precise control of gene expression in neurons. Targeting epigenetic mechanisms, possibly through systemic administration of protein inhibitors (Anderson et al., 2021), viral vectors like AAV in select groups of neurons like cell-type or engram-specific circuits - using the methods described in Guenthner et al. (2013), Maze et al. (2014), Damez-Werno et al. (2016), Campbell et al. (2021) - could lead to breakthrough future translational therapeutics in SUD.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Statements

Author contributions

EA and MT wrote sections of the manuscript and organized the database. Both authors contributed to manuscript revision, read, and approved the submitted version.

Funding

This work was supported by grants from NIH (K01 DA046513, P50DA046373, and DA032708).

Acknowledgments

We thank Christopher W. Cowan for the many discussions on the topics covered in this review.

Conflict of interest

EA is a co-founder of NeuroEpigenix, LLC. The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

  • 1

    AdamsJ. H.BushellG. R. (1989). Changes in the cytoplasmic elements of cultured cells infected with Eimeria vermiformis sporozoites.J Protozool36133138. 10.1111/j.1550-7408.1989.tb01059.x

  • 2

    Aguilar-VallesA.VaissiereT.GriggsE. M.MikaelssonM. A.TakacsI. F.YoungE. J.et al (2014). Methamphetamine-associated memory is regulated by a writer and an eraser of permissive histone methylation.Biol. Psychiatry765765. 10.1016/j.biopsych.2013.09.014

  • 3

    Al AmeriM.Al MansouriS.Al MaamariA.BahiA. (2014). The histone deacetylase (HDAC) inhibitor valproic acid reduces ethanol consumption and ethanol-conditioned place preference in rats.Brain Res.1583122131. 10.1016/j.brainres.2014.07.051

  • 4

    AllfreyV. G.FaulknerR.MirskyA. E. (1964). Acetylation and methylation of histones and their possible role in the regulation of rna synthesis.Proc. Natl. Acad. Sci. U. S. A.51786794. 10.1073/pnas.51.5.786

  • 5

    AllisC. D.JenuweinT. (2016). The molecular hallmarks of epigenetic control.Nat. Rev. Genet.17487500. 10.1038/nrg.2016.59

  • 6

    American Psychiatric Association (2013). Diagnostic and statistical manual of mental disorders : DSM-5.Washington, DC: American Psychiatric Association.

  • 7

    AndersonE. M.LarsonE. B.GuzmanD.WissmanA. M.NeveR. L.NestlerE. J.et al (2018a). Overexpression of the histone dimethyltransferase g9a in nucleus accumbens shell increases cocaine self-administration, stress-induced reinstatement, and anxiety.J. Neurosci.38803813. 10.1523/JNEUROSCI.1657-17.2017

  • 8

    AndersonE. M.PenrodR. D.BarryS. M.HughesB. W.TaniguchiM.CowanC. W. (2018b). It’s a complex issue: emerging connections between epigenetic regulators in drug addiction.Eur. J. Neurosci.5024772491.

  • 9

    AndersonE. M.LopezM. F.KastnerA.MulhollandP. J.BeckerH. C.CowanC. W. (2021). The histone methyltransferase G9a mediates stress-regulated alcohol drinking.Addict. Biol.27:e13060. 10.1111/adb.13060

  • 10

    AndersonE. M.SunH.GuzmanD.TaniguchiM.CowanC. W.MazeI.et al (2019). Knockdown of the histone di-methyltransferase G9a in nucleus accumbens shell decreases cocaine self-administration, stress-induced reinstatement, and anxiety.Neuropsychopharmacology4413701376. 10.1038/s41386-018-0305-4

  • 11

    AndersonE. M.WissmanA. M.ChemplanikalJ.BuzinN.GuzmanD.LarsonE. B.et al (2017). BDNF-TrkB controls cocaine-induced dendritic spines in rodent nucleus accumbens dissociated from increases in addictive behaviors.Proc. Natl. Acad. Sci. U. S. A.11494699474. 10.1073/pnas.1702441114

  • 12

    ArndtD. L.WukitschT. J.GarciaE. J.CainM. (2019). Histone deacetylase inhibition differentially attenuates cue-induced reinstatement: an interaction of environment and acH3K9 expression in the dorsal striatum.Behav. Neurosci.133478488. 10.1037/bne0000333

  • 13

    BahiA.BoyerF.ChandrasekarV.DreyerJ. L. (2008). Role of accumbens BDNF and TrkB in cocaine-induced psychomotor sensitization, conditioned-place preference, and reinstatement in rats.Psychopharmacology199169182. 10.1007/s00213-008-1164-1

  • 14

    BannisterA. J.KouzaridesT. (2011). Regulation of chromatin by histone modifications.Cell Res.21381395. 10.1038/cr.2011.22

  • 15

    BeneventoM.van de MolengraftM.van WestenR.van BokhovenH.KasriN. N. (2015). The role of chromatin repressive marks in cognition and disease: a focus on the repressive complex GLP/G9a.Neurobiol. Learn. Mem.1248896. 10.1016/j.nlm.2015.06.013

  • 16

    Bertran-GonzalezJ.BoschC.MaroteauxM.MatamalesM.HerveD.ValjentE.et al (2008). Opposing patterns of signaling activation in dopamine D1 and D2 receptor-expressing striatal neurons in response to cocaine and haloperidol.J. Neurosci.2856715685. 10.1523/JNEUROSCI.1039-08.2008

  • 17

    BirdA. P.SouthernE. M. (1978). Use of restriction enzymes to study eukaryotic DNA methylation: I. The methylation pattern in ribosomal DNA from Xenopus laevis.J. Mol. Biol.1182747. 10.1016/0022-2836(78)90242-5

  • 18

    BotiaB.LegasteloisR.Alaux-CantinS.NaassilaM. (2012). Expression of ethanol-induced behavioral sensitization is associated with alteration of chromatin remodeling in mice.PLoS One7:e47527. 10.1371/journal.pone.0047527

  • 19

    BuQ.HuZ.ChenF.ZhuR.DengY.ShaoX.et al (2012). Transcriptome analysis of long non-coding RNAs of the nucleus accumbens in cocaine-conditioned mice.J. Neurochem.123790799. 10.1111/jnc.12006

  • 20

    CampbellR. R.KramarE. A.PhamL.BeardwoodJ. H.AugustynskiA. S.LopezA. J.et al (2021). HDAC3 activity within the nucleus accumbens regulates cocaine-induced plasticity and behavior in a cell-type-specific manner.J. Neurosci.4128142827. 10.1523/JNEUROSCI.2829-20.2021

  • 21

    CaputiF. F.Di BenedettoM.CarrettaD.Bastias del Carmen, CandiaS.D’AddarioC.et al (2014). Dynorphin/KOP and nociceptin/NOP gene expression and epigenetic changes by cocaine in rat striatum and nucleus accumbens.Prog. Neuropsychopharmacol. Biol. Psychiatry493646. 10.1016/j.pnpbp.2013.10.016

  • 22

    CaputiF. F.PalmisanoM.CarboniL.CandelettiS.RomualdiP. (2016). Opioid gene expression changes and post-translational histone modifications at promoter regions in the rat nucleus accumbens after acute and repeated 3,4-methylenedioxy-methamphetamine (MDMA) exposure.Pharmacol. Res.114209218. 10.1016/j.phrs.2016.10.023

  • 23

    CarpenterM. D.HuQ.BondA. M.LombrosoS. I.CzarneckiK. S.LimC. J.et al (2020). Nr4a1 suppresses cocaine-induced behavior via epigenetic regulation of homeostatic target genes.Nat. Commun.11:504. 10.1038/s41467-020-14331-y

  • 24

    CarulloN. V. N.Phillips IiiR. A.SimonR. C.SotoS. A. R.HindsJ. E.SalisburyA. J.et al (2020). Enhancer RNAs predict enhancer-gene regulatory links and are critical for enhancer function in neuronal systems.Nucleic Acids Res.4895509570. 10.1093/nar/gkaa671

  • 25

    CatesH. M.LiX.PurushothamanI.KennedyP. J.ShenL.ShahamY.et al (2018). Genome-wide transcriptional profiling of central amygdala and orbitofrontal cortex during incubation of methamphetamine craving.Neuropsychopharmacology4324262434. 10.1038/s41386-018-0158-x

  • 26

    ChandraR.EngelnM.FrancisT. C.KonkalmattP.PatelD.LoboM. K. (2017). A role for peroxisome proliferator-activated receptor gamma coactivator-1alpha in nucleus accumbens neuron subtypes in cocaine action.Biol. Psychiatry81564572. 10.1016/j.biopsych.2016.10.024

  • 27

    ChenH.QiangH.FanK.WangS.ZhengZ. (2014). The snoRNA MBII-52 regulates cocaine-induced conditioned place preference and locomotion in mice.PLoS One9:e99986. 10.1371/journal.pone.0099986

  • 28

    ChenW. S.XuW. J.ZhuH. Q.GaoL.LaiM. J.ZhangF. Q.et al (2016). Effects of histone deacetylase inhibitor sodium butyrate on heroin seeking behavior in the nucleus accumbens in rats.Brain Res.1652151157. 10.1016/j.brainres.2016.10.007

  • 29

    ChristmanJ. K.PriceP.PedrinanL.AcsG. (1977). Correlation between hypomethylation of DNA and expression of globin genes in Friend erythroleukemia cells.Eur. J. Biochem.815361. 10.1111/j.1432-1033.1977.tb11926.x

  • 30

    CiccarelliA.CalzaA.SantoruF.GrassoF.ConcasA.Sassoe-PognettoM.et al (2013). Morphine withdrawal produces ERK-dependent and ERK-independent epigenetic marks in neurons of the nucleus accumbens and lateral septum.Neuropharmacology70168179. 10.1016/j.neuropharm.2012.12.010

  • 31

    CleckJ. N.EckeL. E.BlendyJ. A. (2008). Endocrine and gene expression changes following forced swim stress exposure during cocaine abstinence in mice.Psychopharmacology2011528. 10.1007/s00213-008-1243-3

  • 32

    CovingtonH. E.IIIMazeI.SunH.BomzeH. M.DeMaioK. D.WuE. Y.et al (2011). A role for repressive histone methylation in cocaine-induced vulnerability to stress.Neuron71656670. 10.1016/j.neuron.2011.06.007

  • 33

    CruzF. C.BabinK. R.LeaoR. M.GoldartE. M.BossertJ. M.ShahamY.et al (2014). Role of nucleus accumbens shell neuronal ensembles in context-induced reinstatement of cocaine-seeking.J. Neurosci.3474377446. 10.1523/JNEUROSCI.0238-14.2014

  • 34

    Damez-WernoD.LaPlantQ.SunH.ScobieK. N.DietzD. M.WalkerI. M.et al (2012). Drug experience epigenetically primes Fosb gene inducibility in rat nucleus accumbens.J. Neurosci.321026710272. 10.1523/JNEUROSCI.1290-12.2012

  • 35

    Damez-WernoD. M.SunH.ScobieK. N.ShaoN.RabkinJ.DiasC.et al (2016). Histone arginine methylation in cocaine action in the nucleus accumbens.Proc. Natl. Acad. Sci. U. S. A.11396239628. 10.1073/pnas.1605045113

  • 36

    DashS.BalasubramaniamM.Martinez-RiveraF. J.GodinoA.PeckE. G.PatnaikS.et al (2020). Cocaine-regulated microRNA miR-124 controls poly (ADP-ribose) polymerase-1 expression in neuronal cells.Sci. Rep.10:11197. 10.1038/s41598-020-68144-6

  • 37

    DeansC.MaggertK. A. (2015). What do you mean, “epigenetic”?Genetics199887896. 10.1534/genetics.114.173492

  • 38

    DelcuveG. P.RastegarM.DavieJ. R. (2009). Epigenetic control.J. Cell Physiol.219243250.

  • 39

    DengJ. V.RodriguizR. M.HutchinsonA. N.KimI. H.WetselW. C.WestA. E. (2010). MeCP2 in the nucleus accumbens contributes to neural and behavioral responses to psychostimulants.Nat. Neurosci.1311281136. 10.1038/nn.2614

  • 40

    DengJ. V.WanY.WangX.CohenS.WetselW. C.GreenbergM. E.et al (2014). MeCP2 phosphorylation limits psychostimulant-induced behavioral and neuronal plasticity.J. Neurosci.3445194527. 10.1523/JNEUROSCI.2821-13.2014

  • 41

    DesrosiersR. C.MulderC.FleckensteinB. (1979). Methylation of Herpesvirus saimiri DNA in lymphoid tumor cell lines.Proc. Natl. Acad. Sci. U. S. A.7638393843. 10.1073/pnas.76.8.3839

  • 42

    Di LorenzoA.BedfordM. T. (2011). Histone arginine methylation.FEBS Lett.58520242031.

  • 43

    EberharterA.BeckerP. B. (2002). Histone acetylation: a switch between repressive and permissive chromatin. Second in review series on chromatin dynamics.EMBO Rep.3224229. 10.1093/embo-reports/kvf053

  • 44

    EgervariG.LandryJ.CallensJ.FullardJ. F.RoussosP.KellerE.et al (2017). Striatal H3K27 acetylation linked to glutamatergic gene dysregulation in human heroin abusers holds promise as therapeutic target.Biol. Psychiatry81585594. 10.1016/j.biopsych.2016.09.015

  • 45

    Eipper-MainsJ. E.KiralyD. D.PalakodetiD.MainsR. E.EipperB. A.GraveleyB. R. (2011). microRNA-Seq reveals cocaine-regulated expression of striatal microRNAs.RNA1715291543. 10.1261/rna.2775511

  • 46

    EngmannO.LabonteB.MitchellA.BashtrykovP.CalipariE. S.RosenbluhC.et al (2017). Cocaine-induced chromatin modifications associate with increased expression and three-dimensional looping of Auts2.Biol. Psychiatry82794805. 10.1016/j.biopsych.2017.04.013

  • 47

    FaillaceM. P.ZwillerJ.BernabeuR. O. (2015). Effects of combined nicotine and fluoxetine treatment on adult hippocampal neurogenesis and conditioned place preference.Neuroscience300104115. 10.1016/j.neuroscience.2015.05.017

  • 48

    FarrellyL. A.ThompsonR. E.ZhaoS.LepackA. E.LyuY.BhanuN. V.et al (2019). Histone serotonylation is a permissive modification that enhances TFIID binding to H3K4me3.Nature567535539. 10.1038/s41586-019-1024-7

  • 49

    FengJ.WilkinsonM.LiuX.PurushothamanI.FergusonD.VialouV.et al (2014). Chronic cocaine-regulated epigenomic changes in mouse nucleus accumbens.Genome Biol.15:R65.

  • 50

    FergusonD.KooJ. W.FengJ.HellerE.RabkinJ.HeshmatiM.et al (2013). Essential role of SIRT1 signaling in the nucleus accumbens in cocaine and morphine action.J. Neurosci.331608816098. 10.1523/JNEUROSCI.1284-13.2013

  • 51

    FergusonD.ShaoN.HellerE.FengJ.NeveR.KimH. D.et al (2015). SIRT1-FOXO3a regulate cocaine actions in the nucleus accumbens.J. Neurosci.3531003111. 10.1523/JNEUROSCI.4012-14.2015

  • 52

    FinegershA.FergusonC.MaxwellS.MazariegosD.FarrellD.HomanicsG. E. (2015). Repeated vapor ethanol exposure induces transient histone modifications in the brain that are modified by genotype and brain region.Front. Mol. Neurosci.8:39. 10.3389/fnmol.2015.00039

  • 53

    FlagelS. B.ChaudhuryS.WaselusM.KellyR.SewaniS.ClintonS. M.et al (2016). Genetic background and epigenetic modifications in the core of the nucleus accumbens predict addiction-like behavior in a rat model.Proc. Natl. Acad. Sci. U. S. A.113E2861E2870. 10.1073/pnas.1520491113

  • 54

    FullardJ. F.HaubergM. E.BendlJ.EgervariG.CirnaruM. D.ReachS. M.et al (2018). An atlas of chromatin accessibility in the adult human brain.Genome Res.2812431252. 10.1101/gr.232488.117

  • 55

    GodinoA.JayanthiS.CadetJ. L. (2015). Epigenetic landscape of amphetamine and methamphetamine addiction in rodents.Epigenetics10574580. 10.1080/15592294.2015.1055441

  • 56

    GoodwinD. W.SchulsingerF.HermansenL.GuzeS. B.WinokurG. (1973). Alcohol problems in adoptees raised apart from alcoholic biological parents.Arch. Gen. Psychiatry28238243. 10.1001/archpsyc.1973.01750320068011

  • 57

    GoodwinD. W.SchulsingerF.KnopJ.MednickS.GuzeS. B. (1977). Psychopathology in adopted and nonadopted daughters of alcoholics.Arch. Gen. Psychiatry3410051009. 10.1001/archpsyc.1977.01770210019001

  • 58

    GoodwinD. W.SchulsingerF.MollerN.HermansenL.WinokurG.GuzeS. B. (1974). Drinking problems in adopted and nonadopted sons of alcoholics.Arch. Gen. Psychiatry31164169. 10.1001/archpsyc.1974.01760140022003

  • 59

    GrahamD. L.EdwardsS.BachtellR. K.DiLeoneR. J.RiosM.SelfD. W. (2007). Dynamic BDNF activity in nucleus accumbens with cocaine use increases self-administration and relapse.Nat. Neurosci.1010291037. 10.1038/nn1929

  • 60

    GriffinE. A.Jr.MelasP. A.ZhouR.LiY.MercadoP.KempadooK. A.et al (2017). Prior alcohol use enhances vulnerability to compulsive cocaine self-administration by promoting degradation of HDAC4 and HDAC5.Sci. Adv.3:e1701682. 10.1126/sciadv.1701682

  • 61

    GrunsteinM. (1997). Histone acetylation in chromatin structure and transcription.Nature389349352.

  • 62

    GuY. J.ChenL.ChengL.ZhouM. Y.WangY. (2021). Non-coding RNA: insights into the mechanism of methamphetamine neurotoxicity.Mol. Cell Biochem.47633193328. 10.1007/s11010-021-04160-y

  • 63

    GuenthnerC. J.MiyamichiK.YangH. H.HellerH. C.LuoL. (2013). Permanent genetic access to transiently active neurons via TRAP: targeted recombination in active populations.Neuron78773784. 10.1016/j.neuron.2013.03.025

  • 64

    HamiltonP. J.BurekD. J.LombrosoS. I.NeveR. L.RobisonA. J.NestlerE. J.et al (2018). Cell-type-specific epigenetic editing at the fosb gene controls susceptibility to social defeat stress.Neuropsychopharmacology43272284. 10.1038/npp.2017.88

  • 65

    HellerE. A.CatesH. M.PenaC. J.SunH.ShaoN.FengJ.et al (2014). Locus-specific epigenetic remodeling controls addiction- and depression-related behaviors.Nat. Neurosci.1717201727. 10.1038/nn.3871

  • 66

    HellerE. A.HamiltonP. J.BurekD. D.LombrosoS. I.PenaC. J.NeveR. L.et al (2016). Targeted epigenetic remodeling of the Cdk5 gene in nucleus accumbens regulates cocaine- and stress-evoked behavior.J. Neurosci.3646904697. 10.1523/JNEUROSCI.0013-16.2016

  • 67

    HitchcockL. N.RaybuckJ. D.WoodM. A.LattalK. M. (2019). Effects of a histone deacetylase 3 inhibitor on extinction and reinstatement of cocaine self-administration in rats.Psychopharmacology236517529. 10.1007/s00213-018-5122-2

  • 68

    HollanderJ. A.ImH. I.AmelioA. L.KocerhaJ.BaliP.LuQ.et al (2010). Striatal microRNA controls cocaine intake through CREB signalling.Nature466197202. 10.1038/nature09202

  • 69

    HongL.SchrothG. P.MatthewsH. R.YauP.BradburyE. M. (1993). Studies of the DNA binding properties of histone H4 amino terminus. Thermal denaturation studies reveal that acetylation markedly reduces the binding constant of the H4 “tail” to DNA.J. Biol. Chem.268305314.

  • 70

    HostL.AnglardP.RomieuP.ThibaultC.DembeleD.AunisD.et al (2010). Inhibition of histone deacetylases in rats self-administering cocaine regulates lissencephaly gene-1 and reelin gene expression, as revealed by microarray technique. J. Neurochem. 113, 236247.

  • 71

    HostL.DietrichJ. B.CarougeD.AunisD.ZwillerJ. (2011). Cocaine self-administration alters the expression of chromatin-remodelling proteins; modulation by histone deacetylase inhibition.J. Psychopharmacol.25222229. 10.1177/0269881109348173

  • 72

    HsiangH. L.EppJ. R.van den OeverM. C.YanC.RashidA. J.InselN.et al (2014). Manipulating a “cocaine engram” in mice.J. Neurosci.341411514127. 10.1523/JNEUROSCI.3327-14.2014

  • 73

    HuisingaK. L.Brower-TolandB.ElginS. C. (2006). The contradictory definitions of heterochromatin: transcription and silencing.Chromosoma115110122. 10.1007/s00412-006-0052-x

  • 74

    IkegamiD.NaritaM.ImaiS.MiyashitaK.TamuraR.NaritaM.et al (2010). Epigenetic modulation at the CCR2 gene correlates with the maintenance of behavioral sensitization to methamphetamine.Addict. Biol.15358361. 10.1111/j.1369-1600.2010.00219.x

  • 75

    ImH. I.HollanderJ. A.BaliP.KennyP. J. (2010). MeCP2 controls BDNF expression and cocaine intake through homeostatic interactions with microRNA-212.Nat. Neurosci.1311201127. 10.1038/nn.2615

  • 76

    ItzhakY.LiddieS.AndersonK. L. (2013). Sodium butyrate-induced histone acetylation strengthens the expression of cocaine-associated contextual memory.Neurobiol. Learn. Mem.1023442. 10.1016/j.nlm.2013.03.007

  • 77

    JaenischR.BirdA. (2003). Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals.Nat. Genet.33(Suppl.), 245254. 10.1038/ng1089

  • 78

    JeanblancJ.LemoineS.JeanblancV.Alaux-CantinS.NaassilaM. (2015). The class I-specific HDAC inhibitor MS-275 decreases motivation to consume alcohol and relapse in heavy drinking rats.Int. J. Neuropsychopharmacol.18:pyv029. 10.1093/ijnp/pyv029

  • 79

    JohnstoneA. L.AndradeN. S.BarbierE.KhomtchoukB. B.RienasC. A.LoweK.et al (2021). Dysregulation of the histone demethylase KDM6B in alcohol dependence is associated with epigenetic regulation of inflammatory signaling pathways.Addict. Biol.26:e12816. 10.1111/adb.12816

  • 80

    JonesP. A.TaylorS. M. (1980). Cellular differentiation, cytidine analogs and DNA methylation.Cell208593. 10.1016/0092-8674(80)90237-8

  • 81

    KaldaA.HeidmetsL. T.ShenH. Y.ZharkovskyA.ChenJ. F. (2007). Histone deacetylase inhibitors modulates the induction and expression of amphetamine-induced behavioral sensitization partially through an associated learning of the environment in mice.Behav. Brain Res.1817684. 10.1016/j.bbr.2007.03.027

  • 82

    KennedyP. J.FengJ.RobisonA. J.MazeI.BadimonA.MouzonE.et al (2013). Class I HDAC inhibition blocks cocaine-induced plasticity by targeted changes in histone methylation.Nat. Neurosci.16434440. 10.1038/nn.3354

  • 83

    KennyP. J. (2014). Epigenetics, microRNA, and addiction.Dialogues Clin. Neurosci.16335344. 10.31887/DCNS.2014.16.3/pkenny

  • 84

    KimW. Y.KimS.KimJ. H. (2008). Chronic microinjection of valproic acid into the nucleus accumbens attenuates amphetamine-induced locomotor activity.Neurosci. Lett.4325457. 10.1016/j.neulet.2007.12.005

  • 85

    KoyaE.GoldenS. A.HarveyB. K.Guez-BarberD. H.BerkowA.SimmonsD. E.et al (2009). Targeted disruption of cocaine-activated nucleus accumbens neurons prevents context-specific sensitization.Nat. Neurosci.1210691073. 10.1038/nn.2364

  • 86

    KumarA.ChoiK. H.RenthalW.TsankovaN. M.TheobaldD. E.TruongH. T.et al (2005). Chromatin remodeling is a key mechanism underlying cocaine-induced plasticity in striatum.Neuron48303314. 10.1016/j.neuron.2005.09.023

  • 87

    LachnerM.O’CarrollD.ReaS.MechtlerK.JenuweinT. (2001). Methylation of histone H3 lysine 9 creates a binding site for HP1 proteins.Nature410116120. 10.1038/35065132

  • 88

    LeQ.YanB.YuX.LiY.SongH.ZhuH.et al (2017). Drug-seeking motivation level in male rats determines offspring susceptibility or resistance to cocaine-seeking behaviour.Nat. Commun.8:15527. 10.1038/ncomms15527

  • 89

    LegasteloisR.BotiaB.NaassilaM. (2013). Blockade of ethanol-induced behavioral sensitization by sodium butyrate: descriptive analysis of gene regulations in the striatum.Alcohol. Clin. Exp. Res.3711431153. 10.1111/acer.12088

  • 90

    LepackA. E.WernerC. T.StewartA. F.FultonS. L.ZhongP.FarrellyL. A.et al (2020). Dopaminylation of histone H3 in ventral tegmental area regulates cocaine seeking.Science368197201. 10.1126/science.aaw8806

  • 91

    LevineA.HuangY.DrisaldiB.GriffinE. A.Jr.PollakD. D.XuS.et al (2011). Molecular mechanism for a gateway drug: epigenetic changes initiated by nicotine prime gene expression by cocaine.Sci. Transl. Med.3:107ra109. 10.1126/scitranslmed.3003062

  • 92

    LewisJ. D.MeehanR. R.HenzelW. J.Maurer-FogyI.JeppesenP.KleinF.et al (1992). Purification, sequence, and cellular localization of a novel chromosomal protein that binds to methylated DNA.Cell69905914. 10.1016/0092-8674(92)90610-o

  • 93

    LiJ.ZhuL.SuH.LiuD.YanZ.NiT.et al (2021). Regulation of miR-128 in the nucleus accumbens affects methamphetamine-induced behavioral sensitization by modulating proteins involved in neuroplasticity.Addict. Biol.26:e12881. 10.1111/adb.12881

  • 94

    LiX.CarreriaM. B.WitonskyK. R.ZericT.LofaroO. M.BossertJ. M.et al (2018). Role of dorsal striatum histone deacetylase 5 in incubation of methamphetamine craving.Biol. Psychiatry84213222. 10.1016/j.biopsych.2017.12.008

  • 95

    LiX.DeJosephM. R.UrbanJ. H.BahiA.DreyerJ. L.MeredithG. E.et al (2013). Different roles of BDNF in nucleus accumbens core versus shell during the incubation of cue-induced cocaine craving and its long-term maintenance.J. Neurosci.3311301142. 10.1523/JNEUROSCI.3082-12.2013

  • 96

    LiX.RubioF. J.ZericT.BossertJ. M.KambhampatiS.CatesH. M.et al (2015). Incubation of methamphetamine craving is associated with selective increases in expression of Bdnf and trkb, glutamate receptors, and epigenetic enzymes in cue-activated fos-expressing dorsal striatal neurons.J. Neurosci.3582328244. 10.1523/JNEUROSCI.1022-15.2015

  • 97

    LiY.ZhuR.WangW.FuD.HouJ.JiS.et al (2015). Arginine methyltransferase 1 in the nucleus accumbens regulates behavioral effects of cocaine.J. Neurosci.351289012902. 10.1523/JNEUROSCI.0246-15.2015

  • 98

    LoboM. K.CovingtonH. E.IIIChaudhuryD.FriedmanA. K.SunH.Damez-WernoD.et al (2010). Cell type-specific loss of BDNF signaling mimics optogenetic control of cocaine reward.Science330385390. 10.1126/science.1188472

  • 99

    LugerK.MaderA. W.RichmondR. K.SargentD. F.RichmondT. J. (1997). Crystal structure of the nucleosome core particle at 2.8 A resolution.Nature389251260.

  • 100

    MacaulayI. C.PontingC. P.VoetT. (2017). Single-cell multiomics: multiple measurements from single cells.Trends Genet.33155168. 10.1016/j.tig.2016.12.003

  • 101

    MalvaezM.McQuownS. C.RoggeG. A.AstarabadiM.JacquesV.CarreiroS.et al (2013). HDAC3-selective inhibitor enhances extinction of cocaine-seeking behavior in a persistent manner.Proc. Natl. Acad. Sci. U. S. A.11026472652. 10.1073/pnas.1213364110

  • 102

    MalvaezM.MhillajE.MatheosD. P.PalmeryM.WoodM. A. (2011). CBP in the nucleus accumbens regulates cocaine-induced histone acetylation and is critical for cocaine-associated behaviors.J. Neurosci.311694116948. 10.1523/JNEUROSCI.2747-11.2011

  • 103

    MalvaezM.Sanchis-SeguraC.VoD.LattalK. M.WoodM. A. (2010). Modulation of chromatin modification facilitates extinction of cocaine-induced conditioned place preference.Biol. Psychiatry673643. 10.1016/j.biopsych.2009.07.032

  • 104

    MartinT. A.JayanthiS.McCoyM. T.BrannockC.LadenheimB.GarrettT.et al (2012). Methamphetamine causes differential alterations in gene expression and patterns of histone acetylation/hypoacetylation in the rat nucleus accumbens.PLoS One7:e34236. 10.1371/journal.pone.0034236

  • 105

    MassartR.BarneaR.DikshteinY.SudermanM.MeirO.HallettM.et al (2015). Role of DNA methylation in the nucleus accumbens in incubation of cocaine craving.J. Neurosci.3580428058. 10.1523/JNEUROSCI.3053-14.2015

  • 106

    MazeI.ChaudhuryD.DietzD. M.Von SchimmelmannM.KennedyP. J.LoboM. K.et al (2014). G9a influences neuronal subtype specification in striatum.Nat. Neurosci.17533539. 10.1038/nn.3670

  • 107

    MazeI.CovingtonH. E.IIIDietzD. M.LaPlantQ.RenthalW.RussoS. J.et al (2010). Essential role of the histone methyltransferase G9a in cocaine-induced plasticity.Science327213216. 10.1126/science.1179438

  • 108

    MazeI.FengJ.WilkinsonM. B.SunH.ShenL.NestlerE. J. (2011). Cocaine dynamically regulates heterochromatin and repetitive element unsilencing in nucleus accumbens. Proc. Natl. Acad. Sci. U.S.A.108, 30353040. 10.1073/pnas.1015483108

  • 109

    McCarthyD. M.MorganT. J.Jr.LoweS. E.WilliamsonM. J.SpencerT. J.BiedermanJ.et al (2018). Nicotine exposure of male mice produces behavioral impairment in multiple generations of descendants.PLoS Biol.16:e2006497. 10.1371/journal.pbio.2006497

  • 110

    MeehanR. R.LewisJ. D.BirdA. P. (1992). Characterization of MeCP2, a vertebrate DNA binding protein with affinity for methylated DNA.Nucleic Acids Res.2050855092. 10.1093/nar/20.19.5085

  • 111

    MeehanR. R.LewisJ. D.McKayS.KleinerE. L.BirdA. P. (1989). Identification of a mammalian protein that binds specifically to DNA containing methylated CpGs.Cell58499507. 10.1016/0092-8674(89)90430-3

  • 112

    NesseR. M.BerridgeK. C. (1997). Psychoactive drug use in evolutionary perspective.Science2786366.

  • 113

    NestlerE. J. (2013). Cellular basis of memory for addiction.Dialogues Clin. Neurosci.15431443. 10.31887/DCNS.2013.15.4/enestler

  • 114

    NietoS. J.HaileC. N.QuaveC. B.HardingM. J.NielsenD. A.MeischR. A.et al (2022). Paternal alcohol exposure reduces acquisition of operant alcohol self-administration and affects Bdnf DNA methylation in male and female offspring.Addict. Biol.27:e13078. 10.1111/adb.13078

  • 115

    PandeyS. C.UgaleR.ZhangH.TangL.PrakashA. (2008). Brain chromatin remodeling: a novel mechanism of alcoholism.J. Neurosci.2837293737. 10.1523/JNEUROSCI.5731-07.2008

  • 116

    PascoliV.TuriaultM.LuscherC. (2011). Reversal of cocaine-evoked synaptic potentiation resets drug-induced adaptive behaviour.Nature4817175. 10.1038/nature10709

  • 117

    PascualM.BoixJ.FelipoV.GuerriC. (2009). Repeated alcohol administration during adolescence causes changes in the mesolimbic dopaminergic and glutamatergic systems and promotes alcohol intake in the adult rat.J. Neurochem.108920931. 10.1111/j.1471-4159.2008.05835.x

  • 118

    PastorV.HostL.ZwillerJ.BernabeuR. (2011). Histone deacetylase inhibition decreases preference without affecting aversion for nicotine.J. Neurochem.116636645. 10.1111/j.1471-4159.2010.07149.x

  • 119

    PenrodR. D.CarreiraM. B.TaniguchiM.KumarJ.MaddoxS. A.CowanC. W. (2018). Novel role and regulation of HDAC4 in cocaine-related behaviors.Addict. Biol.23653664. 10.1111/adb.12522

  • 120

    PozhidayevaD. Y.FarrisS. P.GoekeC. M.FirsickE. J.TownsleyK. G.GuizzettiM.et al (2020). Chronic chemogenetic stimulation of the nucleus accumbens produces lasting reductions in binge drinking and ameliorates alcohol-related morphological and transcriptional changes.Brain Sci10:109. 10.3390/brainsci10020109

  • 121

    PriniP.PennaF.SciuccatiE.AlberioT.RubinoT. (2017). Chronic delta(8)-thc exposure differently affects histone modifications in the adolescent and adult rat brain.Int. J. Mol. Sci.18:2094. 10.3390/ijms18102094

  • 122

    ReillyM. T.NoronhaA.GoldmanD.KoobG. F. (2017). Genetic studies of alcohol dependence in the context of the addiction cycle.Neuropharmacology122321. 10.1016/j.neuropharm.2017.01.017

  • 123

    RenthalW.CarleT. L.MazeI.CovingtonH. E.IIITruongH. T.AlibhaiI.et al (2008). Delta FosB mediates epigenetic desensitization of the c-fos gene after chronic amphetamine exposure.J. Neurosci.2873447349. 10.1523/JNEUROSCI.1043-08.2008

  • 124

    RenthalW.KumarA.XiaoG.WilkinsonM.CovingtonH. E.IIIMazeI.et al (2009). Genome-wide analysis of chromatin regulation by cocaine reveals a role for sirtuins.Neuron62335348. 10.1016/j.neuron.2009.03.026

  • 125

    RenthalW.MazeI.KrishnanV.CovingtonH. E.IIIXiaoG.KumarA.et al (2007). Histone deacetylase 5 epigenetically controls behavioral adaptations to chronic emotional stimuli.Neuron56517529. 10.1016/j.neuron.2007.09.032

  • 126

    RoggeG. A.SinghH.DangR.WoodM. A. (2013). HDAC3 is a negative regulator of cocaine-context-associated memory formation.J. Neurosci.3366236632. 10.1523/JNEUROSCI.4472-12.2013

  • 127

    RomieuP.DeschatrettesE.HostL.GobailleS.SandnerG.ZwillerJ. (2011). The inhibition of histone deacetylases reduces the reinstatement of cocaine-seeking behavior in rats.Curr. Neuropharmacol.92125. 10.2174/157015911795017317

  • 128

    RomieuP.HostL.GobailleS.SandnerG.AunisD.ZwillerJ. (2008). Histone deacetylase inhibitors decrease cocaine but not sucrose self-administration in rats.J. Neurosci.2893429348. 10.1523/JNEUROSCI.0379-08.2008

  • 129

    RotemA.RamO.ShoreshN.SperlingR. A.GorenA.WeitzD. A.et al (2015). Single-cell ChIP-seq reveals cell subpopulations defined by chromatin state.Nat. Biotechnol.3311651172. 10.1038/nbt.3383

  • 130

    RotllantD.ArmarioA. (2012). Brain pattern of histone H3 phosphorylation after acute amphetamine administration: its relationship to brain c-fos induction is strongly dependent on the particular brain area.Neuropharmacology6210731081. 10.1016/j.neuropharm.2011.10.019

  • 131

    SaberianH.Asgari TaeiA.Torkaman-BoutorabiA.RiahiE.AminyavariS.NaghizadehA.et al (2021). Effect of histone acetylation on maintenance and reinstatement of morphine-induced conditioned place preference and DeltaFosB expression in the nucleus accumbens and prefrontal cortex of male rats.Behav. Brain Res.414:113477. 10.1016/j.bbr.2021.113477

  • 132

    SakharkarA. J.ZhangH.TangL.BaxstromK.ShiG.MoonatS.et al (2014). Effects of histone deacetylase inhibitors on amygdaloid histone acetylation and neuropeptide Y expression: a role in anxiety-like and alcohol-drinking behaviours.Int. J. Neuropsychopharmacol.1712071220. 10.1017/S1461145714000054

  • 133

    Sanchez-SerranoS. L.CruzS. L.LamasM. (2011). Repeated toluene exposure modifies the acetylation pattern of histones H3 and H4 in the rat brain.Neurosci. Lett.489142147. 10.1016/j.neulet.2010.12.004

  • 134

    Sanchis-SeguraC.Lopez-AtalayaJ. P.BarcoA. (2009). Selective boosting of transcriptional and behavioral responses to drugs of abuse by histone deacetylase inhibition.Neuropsychopharmacology3426422654. 10.1038/npp.2009.125

  • 135

    SchermaM.QvistJ. S.AsokA.HuangS. C.MasiaP.DeiddaM.et al (2020). Cannabinoid exposure in rat adolescence reprograms the initial behavioral, molecular, and epigenetic response to cocaine.Proc. Natl. Acad. Sci. U. S. A.117999110002. 10.1073/pnas.1920866117

  • 136

    SchroederF. A.LewisM. C.FassD. M.WagnerF. F.ZhangY. L.HennigK. M.et al (2013). A selective HDAC 1/2 inhibitor modulates chromatin and gene expression in brain and alters mouse behavior in two mood-related tests.PLoS One8:e71323. 10.1371/journal.pone.0071323

  • 137

    SchuckitM. A.GoodwinD. A.WinokurG. (1972). A study of alcoholism in half siblings.Am. J. Psychiatry12811321136. 10.1176/ajp.128.9.1132

  • 138

    ScobieK. N.Damez-WernoD.SunH.ShaoN.GancarzA.PanganibanC. H.et al (2014). Essential role of poly(ADP-ribosyl)ation in cocaine action.Proc. Natl Acad. Sci. U. S. A.11120052010. 10.1073/pnas.1319703111

  • 139

    SethP.SchollL.RuddR. A.BaconS. (2018). Overdose deaths involving opioids, cocaine, and psychostimulants - United States, 2015-2016.MMWR Morb. Mortal Wkly. Rep.67349358. 10.15585/mmwr.mm6712a1

  • 140

    SharmaR.ParikhM.MishraV.SoniA.RubiS.SahotaP.et al (2021). Antisense-induced downregulation of major circadian genes modulates the expression of histone deacetylase-2 (HDAC-2) and CREB-binding protein (CBP) in the medial shell region of nucleus accumbens of mice exposed to chronic excessive alcohol consumption.J. Neurochem.161819. 10.1111/jnc.15547

  • 141

    ShengJ.LvZ.WangL.ZhouY.HuiB. (2011). Histone H3 phosphoacetylation is critical for heroin-induced place preference.Neuroreport22575580. 10.1097/WNR.0b013e328348e6aa

  • 142

    ShibasakiM.MizunoK.KurokawaK.OhkumaS. (2011). L-type voltage-dependent calcium channels facilitate acetylation of histone H3 through PKCgamma phosphorylation in mice with methamphetamine-induced place preference.J. Neurochem.11810561066. 10.1111/j.1471-4159.2011.07387.x

  • 143

    Simon-O’BrienE.Alaux-CantinS.WarnaultV.ButtoloR.NaassilaM.VilpouxC. (2015). The histone deacetylase inhibitor sodium butyrate decreases excessive ethanol intake in dependent animals.Addict. Biol.20676689. 10.1111/adb.12161

  • 144

    SprowG. M.RinkerJ. A.ThieleT. E. (2014). Histone acetylation in the nucleus accumbens shell modulates ethanol-induced locomotor activity in DBA/2J mice.Alcohol. Clin. Exp. Res.3823772386. 10.1111/acer.12502

  • 145

    SternerD. E.BergerS. L. (2000). Acetylation of histones and transcription-related factors.Microbiol. Mol. Biol. Rev.64435459.

  • 146

    SuH.ZhuL.LiJ.WangR.LiuD.HanW.et al (2019). Regulation of microRNA-29c in the nucleus accumbens modulates methamphetamine -induced locomotor sensitization in mice.Neuropharmacology148160168. 10.1016/j.neuropharm.2019.01.007

  • 147

    SunH.MazeI.DietzD. M.ScobieK. N.KennedyP. J.Damez-WernoD.et al (2012). Morphine epigenomically regulates behavior through alterations in histone H3 lysine 9 dimethylation in the nucleus accumbens.J. Neurosci.321745417464. 10.1523/JNEUROSCI.1357-12.2012

  • 148

    SunJ.WangL.JiangB.HuiB.LvZ.MaL. (2008). The effects of sodium butyrate, an inhibitor of histone deacetylase, on the cocaine- and sucrose-maintained self-administration in rats.Neurosci. Lett.4417276. 10.1016/j.neulet.2008.05.010

  • 149

    TaniguchiM.CarreiraM. B.CooperY. A.BobadillaA. C.HeinsbroekJ. A.KoikeN.et al (2017). HDAC5 and its target gene, npas4, function in the nucleus accumbens to regulate cocaine-conditioned behaviors.Neuron96:e136. 10.1016/j.neuron.2017.09.015

  • 150

    TaniguchiM.CarreiraM. B.SmithL. N.ZirlinB. C.NeveR. L.CowanC. W. (2012). Histone deacetylase 5 limits cocaine reward through cAMP-induced nuclear import.Neuron73108120. 10.1016/j.neuron.2011.10.032

  • 151

    TomasiewiczH. C.JacobsM. M.WilkinsonM. B.WilsonS. P.NestlerE. J.HurdY. L. (2012). Proenkephalin mediates the enduring effects of adolescent cannabis exposure associated with adult opiate vulnerability.Biol. Psychiatry72803810. 10.1016/j.biopsych.2012.04.026

  • 152

    TorresO. V.LadenheimB.JayanthiS.McCoyM. T.KrasnovaI. N.VautierF. A.et al (2016). An acute methamphetamine injection downregulates the expression of several histone deacetylases (HDACs) in the mouse nucleus accumbens: potential regulatory role of HDAC2 expression.Neurotox. Res.303240. 10.1007/s12640-015-9591-3

  • 153

    TorresO. V.McCoyM. T.LadenheimB.JayanthiS.BrannockC.TullochI.et al (2015). CAMKII-conditional deletion of histone deacetylase 2 potentiates acute methamphetamine-induced expression of immediate early genes in the mouse nucleus accumbens.Sci. Rep.5:13396. 10.1038/srep13396

  • 154

    VassolerF. M.OliverD. J.WyseC.BlauA.ShtutmanM.TurnerJ. R.et al (2017). Transgenerational attenuation of opioid self-administration as a consequence of adolescent morphine exposure.Neuropharmacology113271280. 10.1016/j.neuropharm.2016.10.006

  • 155

    VassolerF. M.WhiteS. L.SchmidtH. D.Sadri-VakiliG.PierceR. C. (2013). Epigenetic inheritance of a cocaine-resistance phenotype.Nat. Neurosci.164247. 10.1038/nn.3280

  • 156

    VolkowN. D.BlancoC. (2021). The changing opioid crisis: development, challenges and opportunities.Mol. Psychiatry26218233. 10.1038/s41380-020-0661-4

  • 157

    WangJ. C.KapoorM.GoateA. M. (2012). The genetics of substance dependence.Annu. Rev. Genomics Hum. Genet.13241261.

  • 158

    WangL.LvZ.HuZ.ShengJ.HuiB.SunJ.et al (2010). Chronic cocaine-induced H3 acetylation and transcriptional activation of CaMKIIalpha in the nucleus accumbens is critical for motivation for drug reinforcement.Neuropsychopharmacology35913928. 10.1038/npp.2009.193

  • 159

    WarnaultV.DarcqE.LevineA.BarakS.RonD. (2013). Chromatin remodeling–a novel strategy to control excessive alcohol drinking.Transl. Psychiatry3:e231. 10.1038/tp.2013.4

  • 160

    WernerC. T.AltshulerR. D.ShahamY.LiX. (2021). Epigenetic mechanisms in drug relapse.Biol. Psychiatry89331338. 10.1016/j.biopsych.2020.08.005

  • 161

    WimmerM. E.VassolerF. M.WhiteS. L.SchmidtH. D.SidoliS.HanY.et al (2019). Impaired cocaine-induced behavioral plasticity in the male offspring of cocaine-experienced sires.Eur. J. Neurosci.4911151126. 10.1111/ejn.14310

  • 162

    WolstenholmeJ. T.WarnerJ. A.CapparucciniM. I.ArcherK. J.SheltonK. L.MilesM. F. (2011). Genomic analysis of individual differences in ethanol drinking: evidence for non-genetic factors in C57BL/6 mice.PLoS One6:e21100. 10.1371/journal.pone.0021100

  • 163

    XuW.HongQ.LinZ.MaH.ChenW.ZhuangD.et al (2021). Role of nucleus accumbens microRNA-181a and MeCP2 in incubation of heroin craving in male rats.Psychopharmacology23823132324. 10.1007/s00213-021-05854-3

  • 164

    YangJ.LiL.HongS.ZhangD.ZhouY. (2020). Methamphetamine leads to the alterations of microRNA profiles in the nucleus accumbens of rats.Pharm. Biol.58797805. 10.1080/13880209.2020.1803366

  • 165

    YangX. J. (2004). Lysine acetylation and the bromodomain: a new partnership for signaling.Bioessays2610761087. 10.1002/bies.20104

  • 166

    ZhangX.HuangY.ShiX. (2015). Emerging roles of lysine methylation on non-histone proteins.Cell Mol. Life Sci.7242574272. 10.1007/s00018-015-2001-4

Summary

Keywords

epigenetic, substance use disorder, histone (de)acetylation, histone methlyation, nucleus accumbens, alcohol use disorder (AUD)

Citation

Anderson EM and Taniguchi M (2022) Epigenetic Effects of Addictive Drugs in the Nucleus Accumbens. Front. Mol. Neurosci. 15:828055. doi: 10.3389/fnmol.2022.828055

Received

02 December 2021

Accepted

30 May 2022

Published

23 June 2022

Volume

15 - 2022

Edited by

Shusaku Uchida, Kyoto University, Japan

Reviewed by

Yavin Shaham, National Institute on Drug Abuse (NIH), United States; Hiromasa Funato, Toho University, Japan

Updates

Copyright

*Correspondence: Ethan M. Anderson, Makoto Taniguchi,

This article was submitted to Methods and Model Organisms, a section of the journal Frontiers in Molecular Neuroscience

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics